Juvenile Neuronal Ceroid Lipofuscinosis

Mendelian MONDO:0019262 Pathograph 26 Show in embeddings browser Neuronal Ceroid Lipofuscinosis Lysosomal Storage Disease Neurodegenerative Disease

Juvenile neuronal ceroid lipofuscinosis (juvenile NCL) is a genetically heterogeneous, onset-defined umbrella within the neuronal ceroid lipofuscinoses. It is typically recognized at school age through progressive visual, cognitive, behavioral, seizure, and motor manifestations caused by lysosomal storage neurodegeneration. Classic juvenile NCL is CLN3 disease, but the MONDO entity is deliberately broader than CLN3: juvenile presentations are also documented for PPT1/CLN1, TPP1/CLN2, CLN5, CLN6, MFSD8/CLN7, CLN8, CTSD/CLN10, and ATP13A2/CLN12. The entry therefore models the shared onset/clinical altitude and records each supported genotype, while leaving gene-specific molecular mechanisms in the corresponding genotype entries rather than duplicating CLN3 content.

Ask OpenScientist

Ask a research question about Juvenile Neuronal Ceroid Lipofuscinosis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
10
Pathophys.
11
Phenotypes
1
Gaps
26
Pathograph
9
Genes
3
Medical Actions
9
Subtypes
21
References
1
Deep Research
🏷

Classifications

Lysosomal Storage
neuronal ceroid lipofuscinosis
ICIMD (Inherited Metabolic Disorders)
neuronal ceroid lipofuscinosis
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
All nine genotype branches curated in this juvenile-onset umbrella are caused by biallelic pathogenic variants. The sole dominant NCL branch is adult-onset CLN4/DNAJC5 and is outside this entity.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"With the exception of CLN4 disease, all CLNs are recessive disorders."
The only dominant exception is the adult CLN4 branch; every juvenile genotype represented here is therefore recessive.
◆

Subtypes

9
CLN3 disease, classic juvenile onset
CLN3 hgnc:2074 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in CLN3 (hgnc:2074). hgnc:2074 is a gene from the HUGO Gene Nomenclature Committee.
CLN3 disease is the classic and most familiar juvenile NCL branch. It typically begins between four and seven years with rapidly progressive visual loss, followed by cognitive and behavioral decline, seizures, and motor deterioration.
Show evidence (2 references)
PMID:23838030 SUPPORT Other
"CLN3 disease is the classic juvenile-onset form of neuronal ceroid lipofuscinosis."
This clinical classification review identifies CLN3 as the classic juvenile-onset genotype without equating CLN3 with the entire onset umbrella.
PMID:38500130 SUPPORT Human Clinical
"CLN3 disease (also known as CLN3 Batten disease or Juvenile Neuronal Ceroid Lipofuscinosis) is a rare pediatric neurodegenerative disorder caused by biallelic mutations in CLN3."
A clinical cohort independently identifies the classic juvenile branch and its biallelic CLN3 basis.
CLN1 disease, juvenile onset
PPT1 hgnc:9325 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in PPT1 (hgnc:9325). hgnc:9325 is a gene from the HUGO Gene Nomenclature Committee.
A later-onset PPT1/CLN1 presentation begins between approximately five and ten years. Cognitive decline is followed by seizures, motor decline, and later visual loss, distinguishing its sequence from classic CLN3 disease.
Show evidence (2 references)
PMID:23838030 SUPPORT Other
"A juvenile-onset form of CLN1 disease has also been described and has been referred to “juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits.”"
The review explicitly recognizes a juvenile-onset CLN1 presentation.
PMID:17388982 SUPPORT Human Clinical
"We describe a patient with juvenile-onset NCL phenotype with a new CLN1 mutation and deficient PPT activity."
A molecularly and enzymatically characterized patient independently establishes juvenile-onset PPT1/CLN1 disease.
CLN2 disease, juvenile onset
TPP1 hgnc:2073 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in TPP1 (hgnc:2073). hgnc:2073 is a gene from the HUGO Gene Nomenclature Committee.
Atypical TPP1/CLN2 disease can begin at or after four years rather than in the classic late-infantile interval. Juvenile cases retain lysosomal storage and TPP1-deficiency evidence but may have a slower, overlapping clinical course.
Show evidence (1 reference)
PMID:10191110 SUPPORT Human Clinical
"In this group, we found probands with abundant curvilinear profiles in lysosomal storage material, deficiency of pepstatin-insensitive peptidase, and mutations in the CLN2 gene"
The juvenile-onset cohort included patients with CLN2 mutations, enzyme deficiency, and characteristic lysosomal storage profiles.
CLN5 disease, juvenile onset
CLN5 hgnc:2076 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in CLN5 (hgnc:2076). hgnc:2076 is a gene from the HUGO Gene Nomenclature Committee.
CLN5 disease has a broad onset range that crosses the late-infantile and juvenile intervals. Juvenile presentations may include psychomotor regression, ataxia, myoclonic epilepsy, visual failure, and behavioral problems.
Show evidence (2 references)
PMID:23838030 SUPPORT Other
"The age of onset in CLN5 disease varies from 4 to 17 years, with a mean of 5.6 years."
The documented range includes a substantial juvenile-onset interval.
PMID:20157158 SUPPORT Human Clinical
"The age at disease onset in this cohort is predominantly juvenile rather than late infantile."
A ten-patient pathogenic-CLN5 cohort independently establishes that juvenile onset is common outside the original Finnish classification.
CLN6 disease, late juvenile onset
CLN6 hgnc:2077 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in CLN6 (hgnc:2077). hgnc:2077 is a gene from the HUGO Gene Nomenclature Committee.
A late juvenile CLN6 presentation begins around eight to twelve years and is characterized especially by myoclonic seizures and cognitive decline. This branch is distinct from both earlier variant late-infantile CLN6 and adult CLN6-related Kufs disease.
Show evidence (3 references)
PMID:35359645 SUPPORT Other
"Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual loss;"
The childhood-NCL classification table assigns CLN6 to the late juvenile 8–12-year band and gives its presenting manifestations.
PMID:22883287 SUPPORT Human Clinical
"We describe a multiplex family with autosomal recessive teenage-onset progressive myoclonus epilepsy that had remained undiagnosed despite extensive genetic and pathologic testing."
The family was molecularly diagnosed with CLN6, independently supporting a teenage-onset CLN6 branch.
PMID:34868216 SUPPORT Human Clinical
"We report clinical and genetic findings of three patients from two Greek-Cypriot families (families 915 and 926) with JNCL. All patients were males, and the first symptoms appeared at the age of 6 years."
This primary biallelic-CLN6 case series directly documents juvenile onset and avoids relying on adult Kufs disease as the subtype anchor.
CLN7 disease, juvenile onset
MFSD8 hgnc:28486 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in MFSD8 (hgnc:28486). hgnc:28486 is a gene from the HUGO Gene Nomenclature Committee.
Juvenile MFSD8/CLN7 disease is a protracted branch distinct from the common late-infantile phenotype. Vision loss can begin around ten to twelve and a half years, with seizures following within several years.
Show evidence (1 reference)
PMID:42398224 SUPPORT Human Clinical
"In contrast, both participants with juvenile onset CLN7 disease had normal early development with vision loss as the initial symptom (ages 10-12.5 years), followed by seizure onset within 4 years."
A longitudinal cohort directly distinguishes juvenile CLN7 from the late-infantile phenotype and supplies its onset sequence.
CLN8 disease, juvenile-onset EPMR
CLN8 hgnc:2079 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in CLN8 (hgnc:2079). hgnc:2079 is a gene from the HUGO Gene Nomenclature Committee.
The CLN8-related progressive epilepsy with intellectual disability (EPMR, Northern epilepsy) branch begins with generalized seizures between five and ten years, followed by progressive cognitive impairment. Unlike classic CLN3, visual loss is not its defining presentation.
Show evidence (1 reference)
PMID:10508524 SUPPORT Human Clinical
"Progressive epilepsy with mental retardation (EPMR, MIM 600143) was recently recognized as a new NCL subtype (CLN8). It is an autosomal recessive disorder characterized by onset of generalized seizures between 5 and 10 years, and subsequent progressive mental retardation."
The positional-cloning study establishes both CLN8 identity and onset in the juvenile interval.
CLN10 disease, late juvenile onset
CTSD hgnc:2529 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in CTSD (hgnc:2529). hgnc:2529 is a gene from the HUGO Gene Nomenclature Committee.
A juvenile CTSD/CLN10 presentation begins around eight to twelve years and may present with ataxia, cognitive decline, and visual loss. It is an allelic presentation distinct from congenital and infantile CLN10 disease.
Show evidence (1 reference)
PMID:35359645 SUPPORT Other
"Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual loss;"
The classification table places CTSD/CLN10 in the late juvenile band and lists a distinct ataxia-cognitive-visual presentation.
CLN12 disease, late juvenile onset
ATP13A2 hgnc:30213 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in ATP13A2 (hgnc:30213). hgnc:30213 is a gene from the HUGO Gene Nomenclature Committee.
The ATP13A2/CLN12 juvenile NCL presentation begins in adolescence and is dominated at onset by rigidity and hypokinesia. It overlaps genetically with ATP13A2-related parkinsonism but is included here only at the NCL-pathology/onset altitude documented by the classification source.
Show evidence (2 references)
PMID:35359645 SUPPORT Other
"13–16 yrs CLN12 ATP13A2 NGS Rigidity, hypokinesia"
The review's childhood-NCL table explicitly places ATP13A2/CLN12 in the 13–16-year juvenile-onset band.
PMID:22388936 SUPPORT Human Clinical
"We present a family with typical NCL pathology in which we performed exome sequencing and identified a single homozygous mutation in ATP13A2 that fully segregates with disease within the family."
The founding CLN12 family links recessive ATP13A2 directly to NCL pathology; the juvenile onset is supplied independently by the classification table.
?

Discussions and Knowledge Gaps

1
Is juvenile neuronal ceroid lipofuscinosis identical to CLN3 disease?
CONTROVERSY RESOLVED juvenile_ncl_grouping_vs_cln3_identity
Historical and much modern clinical literature uses JNCL as a synonym for classic CLN3 disease. MONDO:0019262, however, explicitly preserves a separate genetically heterogeneous onset grouping, and the clinical classification literature documents juvenile presentations outside CLN3.
Resolution: Curate MONDO:0019262 as an onset grouping alongside the existing CLN3 genotype entry. Keep CLN3-specific variants, molecular mechanisms, trials, and natural history in `Neuronal_Ceroid_Lipofuscinosis_3.yaml`.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"A juvenile-onset form of CLN1 disease has also been described and has been referred to “juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits.”"
Demonstrates that juvenile NCL terminology is not exclusive to CLN3.
⚙

Pathophysiology

10
PPT1 lysosomal thioesterase deficiency
Biallelic PPT1 lesions can produce deficient palmitoyl-protein thioesterase activity in juvenile-onset CLN1. The molecular steps between this proximal enzyme lesion and storage are not collapsed into a guessed substrate chain.
PPT1 hgnc:9325 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PPT1 (hgnc:9325). hgnc:9325 is a gene from the HUGO Gene Nomenclature Committee.
palmitoyl-protein thioesterase activity GO:0008474 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased palmitoyl-protein thioesterase activity, annotated with palmitoyl-(protein) hydrolase activity (GO:0008474). GO:0008474 is a molecular function from the Gene Ontology. ↓ DECREASED
lysosome GO:0005764 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves lysosome (GO:0005764). GO:0005764 is a cellular component from the Gene Ontology.
Downstream
Lysosomal Ceroid-Lipofuscin Storage PPT1 deficiency converges on the NCL storage phenotype, but omitted substrate and trafficking steps remain incompletely resolved.
Show evidence (1 reference)
PMID:17388982 SUPPORT Human Clinical
"We describe a patient with juvenile-onset NCL phenotype with a new CLN1 mutation and deficient PPT activity."
Direct molecular and biochemical evidence for the proximal juvenile CLN1 lesion.
TPP1 lysosomal peptidase deficiency
Atypical juvenile CLN2 is a biallelic TPP1 branch with deficient pepstatin-insensitive peptidase activity and CLN2 mutations.
TPP1 hgnc:2073 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TPP1 (hgnc:2073). hgnc:2073 is a gene from the HUGO Gene Nomenclature Committee.
pepstatin-insensitive tripeptidyl-peptidase I activity GO:0008240 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased pepstatin-insensitive tripeptidyl-peptidase I activity, annotated with tripeptidyl-peptidase activity (GO:0008240). GO:0008240 is a molecular function from the Gene Ontology. ↓ DECREASED
lysosome GO:0005764 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves lysosome (GO:0005764). GO:0005764 is a cellular component from the Gene Ontology.
Downstream
Lysosomal Ceroid-Lipofuscin Storage Deficient TPP1 lysosomal proteolysis precedes the shared storage node.
Show evidence (1 reference)
PMID:10191110 SUPPORT Human Clinical
"In this group, we found probands with abundant curvilinear profiles in lysosomal storage material, deficiency of pepstatin-insensitive peptidase, and mutations in the CLN2 gene"
Directly links the juvenile cohort's TPP1 lesion to its storage phenotype.
CLN3 lysosomal transmembrane protein dysfunction
Classic juvenile CLN3 begins with biallelic lesions of a lysosomal transmembrane protein whose primary function remains unresolved; the graph therefore does not invent a direct molecular activity.
CLN3 hgnc:2074 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN3 (hgnc:2074). hgnc:2074 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Lysosomal Ceroid-Lipofuscin Storage CLN3 dysfunction converges on fingerprint-type lysosomal storage through unresolved intermediates.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"The CLN3 protein is a lysosomal transmembrane protein of unknown function."
Establishes localization while explicitly preserving functional uncertainty.
CLN5 soluble lysosomal protein dysfunction
Juvenile CLN5 begins with biallelic lesions of a soluble lysosomal glycoprotein. Its proximal biochemical function is left unresolved at this evidence altitude.
CLN5 hgnc:2076 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN5 (hgnc:2076). hgnc:2076 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Lysosomal Ceroid-Lipofuscin Storage CLN5 dysfunction converges on storage through incompletely resolved intermediates.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"The CLN5 protein is a soluble lysosomal glycoprotein of unknown function."
Establishes lysosomal localization without overstating an unknown function.
CLN6 ER transmembrane protein dysfunction
Juvenile CLN6 begins with biallelic lesions of an endoplasmic-reticulum transmembrane protein involved in lysosomal function and acidification.
CLN6 hgnc:2077 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN6 (hgnc:2077). hgnc:2077 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Lysosomal Ceroid-Lipofuscin Storage ER-localized CLN6 dysfunction impairs lysosomal homeostasis before storage accumulates.
Show evidence (1 reference)
PMID:34868216 SUPPORT Human Clinical
"CLN6 encodes an endoplasmic reticulum non-glycosylated transmembrane protein, which is involved in lysosomal acidification."
Supplies a proximal cellular context from a juvenile CLN6 case series.
MFSD8 lysosomal membrane transporter dysfunction
Juvenile CLN7 begins with biallelic MFSD8 lesions affecting a lysosomal membrane member of the major facilitator transporter superfamily.
MFSD8 hgnc:28486 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves MFSD8 (hgnc:28486). hgnc:28486 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Lysosomal Ceroid-Lipofuscin Storage MFSD8 transporter dysfunction converges on storage through unresolved cargo steps.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"The CLN7 protein is a lysosomal membrane protein that belongs to the “major facilitator” superfamily of transporter proteins."
Establishes the proximal protein class and lysosomal localization.
CLN8 ER transmembrane protein dysfunction
Juvenile CLN8 EPMR begins with biallelic lesions of an endoplasmic-reticulum transmembrane protein; the source does not establish a single direct substrate mechanism.
CLN8 hgnc:2079 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN8 (hgnc:2079). hgnc:2079 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Lysosomal Ceroid-Lipofuscin Storage CLN8 dysfunction converges on NCL storage through incompletely known intermediates.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"CLN8 disease is due to mutations in a transmembrane protein of the endoplasmic reticulum of unknown function."
Establishes ER localization and explicitly bounded functional uncertainty.
CTSD lysosomal protease deficiency
Juvenile CLN10 begins with biallelic CTSD lesions causing cathepsin-D deficiency, a lysosomal-enzyme branch distinct from membrane-protein NCLs.
CTSD hgnc:2529 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CTSD (hgnc:2529). hgnc:2529 is a gene from the HUGO Gene Nomenclature Committee.
cathepsin D activity GO:0004190 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased cathepsin D activity, annotated with aspartic-type endopeptidase activity (GO:0004190). GO:0004190 is a molecular function from the Gene Ontology. ↓ DECREASED
lysosome GO:0005764 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves lysosome (GO:0005764). GO:0005764 is a cellular component from the Gene Ontology.
Downstream
Lysosomal Ceroid-Lipofuscin Storage Cathepsin-D deficiency precedes storage through incompletely defined substrates.
ATP13A2 transmembrane protein dysfunction
The CLN12 branch begins with a homozygous ATP13A2 lesion affecting a transmembrane protein and is retained here only where NCL pathology was demonstrated.
ATP13A2 hgnc:30213 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ATP13A2 (hgnc:30213). hgnc:30213 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Lysosomal Ceroid-Lipofuscin Storage ATP13A2 dysfunction converges on NCL storage through unresolved intermediates.
Show evidence (2 references)
PMID:26026925 SUPPORT Other
"many transmembrane proteins with different subcellular locations (CLN3, CLN6, CLN7, CLN8, CLN12)."
Classifies CLN12 among transmembrane-protein NCL lesions.
PMID:22388936 SUPPORT Human Clinical
"We present a family with typical NCL pathology in which we performed exome sequencing and identified a single homozygous mutation in ATP13A2 that fully segregates with disease within the family."
Directly anchors the ATP13A2 lesion to human NCL pathology.
Lysosomal Ceroid-Lipofuscin Storage
The supported juvenile genotypes disrupt different lysosomal or endomembrane proteins, but converge at the disease-family level on intracellular ceroid-lipofuscin storage and progressive neurodegeneration. The onset umbrella does not assert one gene-specific upstream mechanism for all nine branches.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
CLN3 hgnc:2074 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN3 (hgnc:2074). hgnc:2074 is a gene from the HUGO Gene Nomenclature Committee. PPT1 hgnc:9325 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PPT1 (hgnc:9325). hgnc:9325 is a gene from the HUGO Gene Nomenclature Committee. TPP1 hgnc:2073 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TPP1 (hgnc:2073). hgnc:2073 is a gene from the HUGO Gene Nomenclature Committee. CLN5 hgnc:2076 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN5 (hgnc:2076). hgnc:2076 is a gene from the HUGO Gene Nomenclature Committee. CLN6 hgnc:2077 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN6 (hgnc:2077). hgnc:2077 is a gene from the HUGO Gene Nomenclature Committee. MFSD8 hgnc:28486 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves MFSD8 (hgnc:28486). hgnc:28486 is a gene from the HUGO Gene Nomenclature Committee. CLN8 hgnc:2079 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CLN8 (hgnc:2079). hgnc:2079 is a gene from the HUGO Gene Nomenclature Committee. CTSD hgnc:2529 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CTSD (hgnc:2529). hgnc:2529 is a gene from the HUGO Gene Nomenclature Committee. ATP13A2 hgnc:30213 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ATP13A2 (hgnc:30213). hgnc:30213 is a gene from the HUGO Gene Nomenclature Committee.
lysosomal transport GO:0007041 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated lysosomal transport (GO:0007041). GO:0007041 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Visual impairment Retinal storage and degeneration produce progressive visual impairment in the juvenile NCL clinical spectrum, although timing varies by genotype.
Cognitive impairment Progressive neurodegeneration produces cognitive decline and dementia.
Seizure Progressive neuronal dysfunction contributes to epilepsy and seizures.
Motor deterioration Progressive NCL neurodegeneration produces worsening motor disability.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"The neuronal ceroid lipofuscinoses represent a group of disorders characterized by neurodegeneration and intracellular accumulation of an auto-fluorescent lipopigment (ceroid lipofuscin)."
Defines the storage-neurodegeneration convergence modeled at the umbrella level.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Juvenile Neuronal Ceroid Lipofuscinosis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Eye 1
Visual impairment HP:0000505 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual impairment (HP:0000505). HP:0000505 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"He described a juvenile-onset disorder with blindness and progressive dementia."
The historical juvenile NCL description establishes visual loss as a defining feature.
Nervous System 8
Cognitive impairment HP:0100543 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cognitive impairment (HP:0100543). HP:0100543 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"He described a juvenile-onset disorder with blindness and progressive dementia."
The classic juvenile phenotype explicitly includes progressive dementia.
Seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"These 4 primary forms have common features of a neurodegenerative course with epilepsy, dementia, a movement disorder, and retinal degeneration (except adult-onset neuronal ceroid lipofuscinosis), and storage of ceroid lipofuscin in neurons."
Identifies epilepsy as a shared clinical feature of the classic NCL forms.
Atypical behavior HP:0000708 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Atypical behavior (HP:0000708). HP:0000708 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35359645 SUPPORT Other
"Behavioral problems at onset characterize CLN3 and CLN5 diseases"
Restricts the behavior assertion to the two juvenile branches named by the review.
Ataxia HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251). HP:0001251 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"Clinical features include psychomotor regression, ataxia, myoclonic epilepsy, and visual failure, which may be a presenting sign."
Explicitly supports ataxia in the juvenile-age-spanning CLN5 branch.
Myoclonus HP:0001336 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myoclonus (HP:0001336). HP:0001336 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"Ataxia, myoclonus, and, ultimately, spastic quadriparesis follow. The myoclonus may be severe and refractory to treatment."
Directly documents myoclonus in CLN2 disease.
Dementia HP:0000726 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dementia (HP:0000726). HP:0000726 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"He described a juvenile-onset disorder with blindness and progressive dementia."
Directly supports dementia in the historical juvenile phenotype.
Parkinsonism HP:0001300 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Parkinsonism (HP:0001300). HP:0001300 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"In most patients, parkinsonism develops (11 to 13 years of age)."
Provides a genotype-specific later CLN3 motor phenotype.
Developmental regression HP:0002376 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Developmental regression (HP:0002376). HP:0002376 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"Clinical features include psychomotor regression, ataxia, myoclonic epilepsy, and visual failure, which may be a presenting sign."
Explicitly supports regression in the juvenile-age-spanning CLN5 branch.
Other 2
Motor deterioration HP:0002333 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Motor deterioration (HP:0002333). HP:0002333 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"These 4 primary forms have common features of a neurodegenerative course with epilepsy, dementia, a movement disorder, and retinal degeneration (except adult-onset neuronal ceroid lipofuscinosis), and storage of ceroid lipofuscin in neurons."
Supports progressive movement disorder at the shared disease-family level.
Retinal degeneration HP:0000546 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Retinal degeneration (HP:0000546). HP:0000546 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"These 4 primary forms have common features of a neurodegenerative course with epilepsy, dementia, a movement disorder, and retinal degeneration (except adult-onset neuronal ceroid lipofuscinosis), and storage of ceroid lipofuscin in neurons."
Directly identifies retinal degeneration within childhood NCL phenotypes.
🧬

Genetic Associations

9
CLN3 (Pathogenic Variants)
Gene: CLN3 hgnc:2074 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CLN3 (hgnc:2074). hgnc:2074 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (3 references)
PMID:23838030 SUPPORT Other
"CLN3 disease is the classic juvenile-onset form of neuronal ceroid lipofuscinosis."
Directly identifies the causal gene-defined classic juvenile branch.
PMID:38500130 SUPPORT Human Clinical
"CLN3 disease (also known as CLN3 Batten disease or Juvenile Neuronal Ceroid Lipofuscinosis) is a rare pediatric neurodegenerative disorder caused by biallelic mutations in CLN3."
The clinical cohort directly supports biallelic CLN3 variants in the classic juvenile presentation.
PMID:31926949 SUPPORT Human Clinical
"The most common sequence variant in CLN3 is a homozygous 1 kb deletion, accounting for approximately 85% of cases of JNCL."
Identifies the recurrent deletion that requires deletion/copy-number-aware molecular testing.
PPT1 (Pathogenic Variants)
Gene: PPT1 hgnc:9325 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PPT1 (hgnc:9325). hgnc:9325 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (3 references)
PMID:23838030 SUPPORT Other
"A juvenile-onset form of CLN1 disease has also been described and has been referred to “juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits.”"
Explicit evidence for the PPT1/CLN1 juvenile allelic presentation.
PMID:17388982 SUPPORT Human Clinical
"We describe a patient with juvenile-onset NCL phenotype with a new CLN1 mutation and deficient PPT activity."
Molecular and enzyme evidence directly supports juvenile PPT1/CLN1 disease.
PMID:27553520 SUPPORT Other
"Carrier frequency was dependent on ethnicity, with the highest (1/75) observed for PPT1 in the Finnish."
Supplies ancestry-specific carrier-frequency and founder-allele context; it does not establish the frequency of the juvenile presentation itself.
TPP1 (Pathogenic Variants)
Gene: TPP1 hgnc:2073 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TPP1 (hgnc:2073). hgnc:2073 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:10191110 SUPPORT Human Clinical
"In this group, we found probands with abundant curvilinear profiles in lysosomal storage material, deficiency of pepstatin-insensitive peptidase, and mutations in the CLN2 gene"
The juvenile-onset cohort directly links CLN2 mutations, enzyme deficiency, and NCL storage pathology.
PMID:27553520 SUPPORT Other
"PPT1, TPP1 and CLN3 carrier frequencies were found to be the highest of the NCLs, each at ~1/500."
Adds ancestry-stratified carrier context without treating carrier frequency as affected prevalence or penetrance.
CLN5 (Pathogenic Variants)
Gene: CLN5 hgnc:2076 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CLN5 (hgnc:2076). hgnc:2076 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:23838030 SUPPORT Other
"The age of onset in CLN5 disease varies from 4 to 17 years, with a mean of 5.6 years."
The documented range spans juvenile age and supports this branch.
PMID:20157158 SUPPORT Human Clinical
"The age at disease onset in this cohort is predominantly juvenile rather than late infantile."
Pathogenic CLN5 variants were found in a predominantly juvenile-onset cohort.
CLN6 (Pathogenic Variants)
Gene: CLN6 hgnc:2077 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CLN6 (hgnc:2077). hgnc:2077 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (4 references)
PMID:35359645 SUPPORT Other
"Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual loss;"
Places CLN6 explicitly in the review's late juvenile row.
PMID:22883287 SUPPORT Human Clinical
"The affected gene is CLN6, previously known to underlie variant late-infantile and adult-onset neuronal ceroid lipofuscinoses."
Genetic diagnosis identifies CLN6 in the teenage-onset family.
PMID:34868216 SUPPORT Human Clinical
"We report clinical and genetic findings of three patients from two Greek-Cypriot families (families 915 and 926) with JNCL. All patients were males, and the first symptoms appeared at the age of 6 years."
A primary molecular case series directly supports juvenile-onset CLN6 disease rather than relying only on a classification review.
+ 1 more reference
MFSD8 (Pathogenic Variants)
Gene: MFSD8 hgnc:28486 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is MFSD8 (hgnc:28486). hgnc:28486 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:19201763 SUPPORT Human Clinical
"In one patient with an in-frame amino acid substitution mutation in CLN7/MFSD8, the disease onset was later and the disease course less aggressive than in variant late-infantile NCL."
Human molecular evidence directly links MFSD8 to a later-onset, protracted NCL presentation.
PMID:42398224 SUPPORT Human Clinical
"We enrolled 5 participants with late infantile onset and 2 participants with juvenile onset CLN7 disease."
The longitudinal cohort independently confirms a juvenile CLN7 branch.
CLN8 (Pathogenic Variants)
Gene: CLN8 hgnc:2079 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CLN8 (hgnc:2079). hgnc:2079 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:10508524 SUPPORT Human Clinical
"Here we report the positional cloning of a novel gene, CLN8, which is mutated in EPMR."
The positional-cloning study directly establishes CLN8 as the EPMR gene.
CTSD (Pathogenic Variants)
Gene: CTSD hgnc:2529 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CTSD (hgnc:2529). hgnc:2529 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:35359645 SUPPORT Other
"Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual loss;"
Places CTSD/CLN10 explicitly in the review's late juvenile row.
ATP13A2 (Pathogenic Variants)
Gene: ATP13A2 hgnc:30213 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ATP13A2 (hgnc:30213). hgnc:30213 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:35359645 SUPPORT Other
"13–16 yrs CLN12 ATP13A2 NGS Rigidity, hypokinesia"
Explicitly identifies ATP13A2 as the CLN12 late juvenile genotype.
PMID:22388936 SUPPORT Human Clinical
"We present a family with typical NCL pathology in which we performed exome sequencing and identified a single homozygous mutation in ATP13A2 that fully segregates with disease within the family."
Direct human genetic and pathological evidence for ATP13A2-related NCL.
💊

Medical Actions

3
Supportive care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Management is genotype- and symptom-specific and remains primarily supportive. This onset umbrella does not extrapolate a therapy studied in CLN3 or another single genotype to every juvenile NCL branch.
Show evidence (1 reference)
PMID:35359645 SUPPORT Other
"palliative care and symptomatic treatments which are still the main therapeutic interventions."
Supports supportive and palliative management across NCLs.
Antiseizure pharmacotherapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: anticonvulsant agent NCIT:C264 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses anticonvulsant agent (NCIT:C264). NCIT:C264 is a therapeutic agent from the NCI Thesaurus.
Antiseizure medication is used to reduce seizure burden. Drug choice must account for genotype and seizure semiology, and treatment is not represented as disease-modifying. Agents known to exacerbate myoclonus should be avoided; the cited clinical review specifically cautions against carbamazepine.
Target Phenotypes: Seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:35359645 SUPPORT Other
"there is consensus that medications for epilepsy are used to alleviate seizure burden"
Supports symptomatic seizure-burden reduction rather than cure.
PMID:35359645 SUPPORT Other
"those which are known to exacerbate myoclonus are best avoided. The most commonly used anti-seizure medications are valproate, levetiracetam and the benzodiazepines in varying combinati ons. Carbamazepine is avoided."
Supports the narrow prescribing caution; no uncited list of additional drugs is inferred from it.
Cerliponase alfa for the TPP1/CLN2 branch
Action: enzyme replacement therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is enzyme replacement therapy, annotated with Protein Replacement Therapy (NCIT:C16221). NCIT:C16221 is a clinical intervention from the NCI Thesaurus. Ontology label: Protein Replacement Therapy NCIT:C16221
Intracerebroventricular recombinant human TPP1 enzyme replacement targets the proximal enzyme lesion in CLN2 disease and slows motor-language decline. The efficacy trial summarized by the source focused on late-infantile CLN2, not a juvenile-onset-stratified cohort; use for atypical juvenile CLN2 therefore requires genotype confirmation and specialist assessment rather than extrapolation to every juvenile NCL branch.
Mechanism Target:
RESTORES TPP1 lysosomal peptidase deficiency — Cerliponase alfa replaces the deficient TPP1 enzyme in the CLN2 branch.
Show evidence (1 reference)
PMID:31884868 SUPPORT Human Clinical
"Cerliponase alfa is recombinant human tripeptidyl peptidase 1 enzyme replacement therapy."
Directly identifies the replacement protein and proximal treatment target.
Show evidence (2 references)
PMID:31884868 SUPPORT Human Clinical
"Treatment with intracerebroventricular cerliponase alfa resulted in slower decline of motor and language functions compared with natural history controls."
Supplies the clinical efficacy signal while the description preserves onset-scope limits.
PMID:31884868 SUPPORT Human Clinical
"Cerliponase alfa is the first therapy for neuronal ceroid lipofuscinosis type 2 that targets the disease etiology."
Supports the etiologic, branch-specific treatment classification.
🔬

Biochemical Markers

1
Autofluorescent ceroid-lipofuscin storage (INCREASED)
Context: Intracellular autofluorescent ceroid-lipofuscin is the defining storage readout across NCLs. Ultrastructural morphology differs by genotype, so no single inclusion pattern is asserted for the entire juvenile umbrella.
Pathograph Readouts
Readout Of Lysosomal Ceroid-Lipofuscin Storage Positive Diagnostic
Increased autofluorescent lipopigment reports the shared storage node.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"The neuronal ceroid lipofuscinoses represent a group of disorders characterized by neurodegeneration and intracellular accumulation of an auto-fluorescent lipopigment (ceroid lipofuscin)."
Defines the diagnostic storage material.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"The neuronal ceroid lipofuscinoses represent a group of disorders characterized by neurodegeneration and intracellular accumulation of an auto-fluorescent lipopigment (ceroid lipofuscin)."
Supports increased intracellular ceroid-lipofuscin as the shared readout.
🔬

Diagnosis

5
Broad molecular panel with deletion and copy-number analysis
A child with a juvenile NCL phenotype should undergo molecular testing broad enough to distinguish the supported CLN3, PPT1, TPP1, CLN5, CLN6, MFSD8, CLN8, CTSD, and ATP13A2 branches. Age and presenting sequence guide interpretation but do not reliably identify the genotype by themselves. The assay must include deletion/copy-number detection, because the common CLN3 lesion and other multi-exon deletions can be missed by sequence-only pipelines.
Show evidence (2 references)
PMID:23838030 SUPPORT Other
"Most experts in neuronal ceroid lipofuscinosis now recommend primary classification by gene (or protein), with secondary classification by age of onset and clinical features."
Supports gene-first classification for an onset-defined clinical presentation.
PMID:31926949 SUPPORT Human Clinical
"The most common sequence variant in CLN3 is a homozygous 1 kb deletion, accounting for approximately 85% of cases of JNCL."
A recurrent deletion in the classic branch makes deletion/copy-number coverage an essential part of the molecular workflow.
Lysosomal enzyme assay triage
PPT1, TPP1, and CTSD activity assays provide a rapid biochemical route into the CLN1, CLN2, and CLN10 branches, respectively. Enzyme results complement rather than replace biallelic molecular confirmation.
Show evidence (1 reference)
PMID:35359645 SUPPORT Other
"enzymatic assays became available for four lysosomal enzym es: CTSD, CTSF , PPT1, and TPP1"
The diagnostic review identifies CTSD, PPT1, and TPP1 among the lysosomal enzymes with available biochemical assays; the spacing reflects the source PDF extraction.
Peripheral blood film and storage-inclusion screening
In a child with rapid bilateral visual loss suggestive of classic CLN3, vacuolated lymphocytes on peripheral blood film provide a rapid screening clue and fingerprint lysosomal inclusions can be demonstrated by electron microscopy. These findings do not identify every non-CLN3 juvenile branch.
Show evidence (1 reference)
PMID:31926949 SUPPORT Human Clinical
"Blood film microscopy performed for all 8 patients demonstrated vacuolated lymphocytes. Electron microscopy was done sequentially in 7 patients, and all showed lysosomal (fingerprint) inclusions."
Directly supports both screening steps in a molecularly confirmed CLN3 juvenile cohort.
Retinal electrophysiology and multimodal imaging
Full-field electroretinography, fundus autofluorescence, and OCT can expose severe generalized retinal and macular dysfunction when rapid visual loss raises classic CLN3 suspicion. These are phenotype-directed adjuncts, not a gene-independent confirmation test for the whole umbrella.
Show evidence (2 references)
PMID:31926949 SUPPORT Human Clinical
"Full-field and flash ERGs were recorded in all patients under photopic and scotopic conditions. Cases 1, 2, 4, and 5 had undetectable ERGs, in keeping with severe rod and cone photoreceptor dysfunction"
Demonstrates a severe electrophysiologic retinal signature in CLN3 disease.
PMID:36964447 SUPPORT Human Clinical
"Best corrected visual acuity (BCVA), electroretinogram (ERG), ultra-widefield (UWF) fundus photography and fundus autofluorescence (FAF), and optical coherence tomography (OCT) studies were undertaken."
Independently documents the multimodal retinal assessment set in CLN3 disease.
Ultrastructural storage-pattern analysis
Electron microscopy can classify granular osmiophilic, curvilinear, fingerprint, or rectilinear storage patterns and thereby focus biochemical and molecular testing. Overlap between newer genotype-defined NCLs means ultrastructure remains supportive rather than definitive.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"The distinctive ultrastructural patterns are granular osmiophilic deposits in infantile neuronal ceroid lipofuscinosis, curvilinear profiles in late-infantile neuronal ceroid lipofuscinosis, fingerprint bodies in juvenile neuronal ceroid lipofuscinosis, and rectilinear profiles in adult-onset..."
Defines the classic electron-microscopy patterns while the adjacent review text cautions that newer forms overlap.
📈

Progression

9
Classic CLN3 onset
CLN3 disease, classic juvenile onset Age: 4 to 7 years
Rapid visual loss is usually followed by cognitive decline, behavioral problems, seizures, and later parkinsonian or other motor manifestations.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"The typical age of onset in CLN3 disease is between 4 years and 7 years, with insidious, but rapidly progressive, vision loss."
Defines the onset window and initial clinical feature for classic CLN3.
Juvenile CLN1 onset and progression
CLN1 disease, juvenile onset Age: 5 to 10 years
Cognitive decline begins first; seizures, motor decline, and visual loss follow over later childhood and adolescence.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"The juvenile-onset form starts between the ages of 5 years and 10 years, with cognitive decline followed by seizures (7 to 17 years), motor decline (7 to 15 years), and vision loss (10 to 14 years)."
Provides a genotype-specific juvenile CLN1 sequence rather than projecting the CLN3 sequence onto all subtypes.
Atypical juvenile CLN2 onset
CLN2 disease, juvenile onset Age: About or after 4 years
Atypical TPP1/CLN2 cases begin later and may progress more slowly than classic late-infantile CLN2 disease.
Show evidence (1 reference)
PMID:10191110 SUPPORT Human Clinical
"Most of the typical and atypical probands had onset of symptoms about or after 4 years of age."
The molecularly evaluated juvenile cohort supplies the later CLN2 onset boundary without projecting the classic late-infantile trajectory.
Juvenile CLN5 onset
CLN5 disease, juvenile onset Age: 4 to 17 years
The CLN5 onset distribution crosses clinical age bands, so this entry covers only CLN5 cases presenting in the juvenile interval.
Show evidence (1 reference)
PMID:23838030 SUPPORT Other
"The age of onset in CLN5 disease varies from 4 to 17 years, with a mean of 5.6 years."
Supports a genuine juvenile subset without relabeling every CLN5 case.
Late juvenile CLN6 onset
CLN6 disease, late juvenile onset Age: 8 to 12 years
Myoclonic seizures and cognitive decline characterize the late juvenile CLN6 presentation represented in this onset grouping.
Show evidence (1 reference)
PMID:35359645 SUPPORT Other
"Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual loss;"
The table places CLN6 in the 8–12-year row and gives its presenting manifestations.
Juvenile CLN7 onset
CLN7 disease, juvenile onset Age: 10 to 12.5 years
Vision loss is the initial manifestation, followed by seizures within four years in the directly observed juvenile CLN7 cohort.
Show evidence (1 reference)
PMID:42398224 SUPPORT Human Clinical
"In contrast, both participants with juvenile onset CLN7 disease had normal early development with vision loss as the initial symptom (ages 10-12.5 years), followed by seizure onset within 4 years."
Provides the juvenile CLN7 onset window and its vision-first sequence.
Juvenile CLN8 EPMR onset
CLN8 disease, juvenile-onset EPMR Age: 5 to 10 years
Generalized seizures precede progressive cognitive impairment; the course does not require the early visual-loss sequence typical of classic CLN3.
Show evidence (1 reference)
PMID:10508524 SUPPORT Human Clinical
"It is an autosomal recessive disorder characterized by onset of generalized seizures between 5 and 10 years, and subsequent progressive mental retardation."
Directly defines the juvenile-onset sequence of the CLN8 EPMR branch.
Late juvenile CLN10 onset
CLN10 disease, late juvenile onset Age: 8 to 12 years
Ataxia, cognitive decline, and visual loss characterize the late juvenile CTSD/CLN10 presentation represented in this onset grouping.
Show evidence (1 reference)
PMID:35359645 SUPPORT Other
"Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual loss;"
The table places CTSD/CLN10 in the 8–12-year row and gives its presenting manifestations.
Late juvenile CLN12 onset
CLN12 disease, late juvenile onset Age: 13 to 16 years
Rigidity and hypokinesia characterize the ATP13A2/CLN12 presentation in the oldest juvenile age stratum represented in this onset grouping.
Show evidence (1 reference)
PMID:35359645 SUPPORT Other
"13–16 yrs CLN12 ATP13A2 NGS Rigidity, hypokinesia"
The table places ATP13A2/CLN12 in the 13–16-year row and identifies its motor presentation.
📊

Prevalence

3
Sweden, Norway, and Denmark (1990s ascertainment)
Point Prevalence 0.31–0.65 per 100,000 1–9 per 1,000,000
Clinically classified juvenile NCL point prevalence varied substantially across Scandinavian countries before comprehensive gene-first diagnosis. Sweden, Norway, and Denmark occupied the 3.1-6.5-per-million range; these historical estimates should not be interpreted as genotype-specific rates.
Show evidence (1 reference)
PMID:9151309 SUPPORT Human Clinical
"The prevalence of juvenile NCL was thus 4.6, 12.2, 6.5, 3.1 and 11 per million inhabitants in Sweden, Finland, Norway, Denmark, and Iceland, respectively."
The population study directly supplies country-specific point-prevalence estimates; this record captures the three countries within the lower prevalence band.
Finland and Iceland (1990s ascertainment)
Point Prevalence 1.1–1.22 per 100,000 1–9 per 100,000
Finland and Iceland had higher historical juvenile NCL point-prevalence estimates than the other Scandinavian countries studied. The cohort was defined clinically, so the estimate is not assigned to one CLN genotype.
Show evidence (1 reference)
PMID:9151309 SUPPORT Human Clinical
"The prevalence of juvenile NCL was thus 4.6, 12.2, 6.5, 3.1 and 11 per million inhabitants in Sweden, Finland, Norway, Denmark, and Iceland, respectively."
The study reports 12.2 and 11 juvenile-NCL cases per million inhabitants for Finland and Iceland, respectively.
Scandinavian live births, 1976-1985
Birth Prevalence 2.0–7.0 per 100,000 1–9 per 100,000
The source calls this measure incidence, but its denominator is live births; it is therefore represented as birth prevalence. Historical clinical classification and founder effects likely contributed to the geographic range.
Show evidence (1 reference)
PMID:9151309 SUPPORT Human Clinical
"The incidence was 2.2 per 100,000 live births in Sweden, 4.8 in Finland, 3.7 in Norway, 2.0 in Denmark, and 7.0 in Iceland."
Directly reports the country-specific juvenile-NCL live-birth range used here.
{ }

Source YAML

click to show 
name: Juvenile Neuronal Ceroid Lipofuscinosis
category: Mendelian
creation_date: '2026-08-08T00:00:00Z'
description: >
  Juvenile neuronal ceroid lipofuscinosis (juvenile NCL) is a genetically
  heterogeneous, onset-defined umbrella within the neuronal ceroid
  lipofuscinoses. It is typically recognized at school age through progressive
  visual, cognitive, behavioral, seizure, and motor manifestations caused by
  lysosomal storage neurodegeneration. Classic juvenile NCL is CLN3 disease,
  but the MONDO entity is deliberately broader than CLN3: juvenile
  presentations are also documented for PPT1/CLN1, TPP1/CLN2, CLN5, CLN6,
  MFSD8/CLN7, CLN8, CTSD/CLN10, and ATP13A2/CLN12. The entry therefore models
  the shared onset/clinical altitude and records each supported genotype, while
  leaving gene-specific molecular mechanisms in the corresponding genotype
  entries rather than duplicating CLN3 content.
disease_term:
  preferred_term: juvenile neuronal ceroid lipofuscinosis
  term:
    id: MONDO:0019262
    label: juvenile neuronal ceroid lipofuscinosis
synonyms:
- juvenile NCL
- JNCL
- Spielmeyer-Vogt disease
- Batten-Spielmeyer-Vogt disease
- juvenile Batten disease
prevalence:
- population: Sweden, Norway, and Denmark (1990s ascertainment)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_low: 0.31
  rate_high: 0.65
  percentage: 3.1-6.5 per million inhabitants
  notes: >
    Clinically classified juvenile NCL point prevalence varied substantially
    across Scandinavian countries before comprehensive gene-first diagnosis.
    Sweden, Norway, and Denmark occupied the 3.1-6.5-per-million range; these
    historical estimates should not be interpreted as genotype-specific rates.
  evidence:
  - reference: PMID:9151309
    reference_title: "Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The prevalence of juvenile NCL was thus 4.6, 12.2, 6.5, 3.1 and 11 per
      million inhabitants in Sweden, Finland, Norway, Denmark, and Iceland,
      respectively.
    explanation: >
      The population study directly supplies country-specific point-prevalence
      estimates; this record captures the three countries within the lower
      prevalence band.
- population: Finland and Iceland (1990s ascertainment)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.1
  rate_high: 1.22
  percentage: 11-12.2 per million inhabitants
  notes: >
    Finland and Iceland had higher historical juvenile NCL point-prevalence
    estimates than the other Scandinavian countries studied. The cohort was
    defined clinically, so the estimate is not assigned to one CLN genotype.
  evidence:
  - reference: PMID:9151309
    reference_title: "Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The prevalence of juvenile NCL was thus 4.6, 12.2, 6.5, 3.1 and 11 per
      million inhabitants in Sweden, Finland, Norway, Denmark, and Iceland,
      respectively.
    explanation: >
      The study reports 12.2 and 11 juvenile-NCL cases per million inhabitants
      for Finland and Iceland, respectively.
- population: Scandinavian live births, 1976-1985
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 2.0
  rate_high: 7.0
  percentage: 2.0-7.0 per 100,000 live births
  notes: >
    The source calls this measure incidence, but its denominator is live births;
    it is therefore represented as birth prevalence. Historical clinical
    classification and founder effects likely contributed to the geographic
    range.
  evidence:
  - reference: PMID:9151309
    reference_title: "Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The incidence was 2.2 per 100,000 live births in Sweden, 4.8 in Finland,
      3.7 in Norway, 2.0 in Denmark, and 7.0 in Iceland.
    explanation: >
      Directly reports the country-specific juvenile-NCL live-birth range used
      here.
parents:
- Neuronal Ceroid Lipofuscinosis
- Lysosomal Storage Disease
- Neurodegenerative Disease
has_subtypes:
- name: CLN3 disease, classic juvenile onset
  description: >
    CLN3 disease is the classic and most familiar juvenile NCL branch. It
    typically begins between four and seven years with rapidly progressive
    visual loss, followed by cognitive and behavioral decline, seizures, and
    motor deterioration.
  genes:
  - preferred_term: CLN3
    term:
      id: hgnc:2074
      label: CLN3
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      CLN3 disease is the classic juvenile-onset form of neuronal ceroid
      lipofuscinosis.
    explanation: >
      This clinical classification review identifies CLN3 as the classic
      juvenile-onset genotype without equating CLN3 with the entire onset
      umbrella.
  - reference: PMID:38500130
    reference_title: "The parent and family impact of CLN3 disease: an observational survey-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CLN3 disease (also known as CLN3 Batten disease or Juvenile Neuronal
      Ceroid Lipofuscinosis) is a rare pediatric neurodegenerative disorder
      caused by biallelic mutations in CLN3.
    explanation: >
      A clinical cohort independently identifies the classic juvenile branch
      and its biallelic CLN3 basis.
- name: CLN1 disease, juvenile onset
  description: >
    A later-onset PPT1/CLN1 presentation begins between approximately five and
    ten years. Cognitive decline is followed by seizures, motor decline, and
    later visual loss, distinguishing its sequence from classic CLN3 disease.
  genes:
  - preferred_term: PPT1
    term:
      id: hgnc:9325
      label: PPT1
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A juvenile-onset form of CLN1 disease has also been described and has
      been referred to “juvenile neuronal ceroid lipofuscinosis with granular
      osmiophilic deposits.”
    explanation: >
      The review explicitly recognizes a juvenile-onset CLN1 presentation.
  - reference: PMID:17388982
    reference_title: "Juvenile-onset neuronal ceroid lipofuscinosis with infantile CLN1 mutation and palmitoyl-protein thioesterase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe a patient with juvenile-onset NCL phenotype with a new CLN1
      mutation and deficient PPT activity.
    explanation: >
      A molecularly and enzymatically characterized patient independently
      establishes juvenile-onset PPT1/CLN1 disease.
- name: CLN2 disease, juvenile onset
  description: >
    Atypical TPP1/CLN2 disease can begin at or after four years rather than in
    the classic late-infantile interval. Juvenile cases retain lysosomal
    storage and TPP1-deficiency evidence but may have a slower, overlapping
    clinical course.
  genes:
  - preferred_term: TPP1
    term:
      id: hgnc:2073
      label: TPP1
  evidence:
  - reference: PMID:10191110
    reference_title: "Reevaluation of neuronal ceroid lipofuscinoses: atypical juvenile onset may be the result of CLN2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this group, we found probands with abundant curvilinear profiles in
      lysosomal storage material, deficiency of pepstatin-insensitive
      peptidase, and mutations in the CLN2 gene
    explanation: >
      The juvenile-onset cohort included patients with CLN2 mutations, enzyme
      deficiency, and characteristic lysosomal storage profiles.
- name: CLN5 disease, juvenile onset
  description: >
    CLN5 disease has a broad onset range that crosses the late-infantile and
    juvenile intervals. Juvenile presentations may include psychomotor
    regression, ataxia, myoclonic epilepsy, visual failure, and behavioral
    problems.
  genes:
  - preferred_term: CLN5
    term:
      id: hgnc:2076
      label: CLN5
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The age of onset in CLN5 disease varies from 4 to 17 years, with a mean
      of 5.6 years.
    explanation: >
      The documented range includes a substantial juvenile-onset interval.
  - reference: PMID:20157158
    reference_title: "CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The age at disease onset in this cohort is predominantly juvenile rather
      than late infantile.
    explanation: >
      A ten-patient pathogenic-CLN5 cohort independently establishes that
      juvenile onset is common outside the original Finnish classification.
- name: CLN6 disease, late juvenile onset
  description: >
    A late juvenile CLN6 presentation begins around eight to twelve years and
    is characterized especially by myoclonic seizures and cognitive decline.
    This branch is distinct from both earlier variant late-infantile CLN6 and
    adult CLN6-related Kufs disease.
  genes:
  - preferred_term: CLN6
    term:
      id: hgnc:2077
      label: CLN6
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay
      Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual
      loss;
    explanation: >
      The childhood-NCL classification table assigns CLN6 to the late juvenile
      8–12-year band and gives its presenting manifestations.
  - reference: PMID:22883287
    reference_title: "Mutation of the CLN6 gene in teenage-onset progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe a multiplex family with autosomal recessive teenage-onset
      progressive myoclonus epilepsy that had remained undiagnosed despite
      extensive genetic and pathologic testing.
    explanation: >
      The family was molecularly diagnosed with CLN6, independently supporting
      a teenage-onset CLN6 branch.
  - reference: PMID:34868216
    reference_title: "A Novel CLN6 Variant Associated With Juvenile Neuronal Ceroid Lipofuscinosis in Patients With Absence of Visual Loss as a Presenting Feature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report clinical and genetic findings of three patients from two
      Greek-Cypriot families (families 915 and 926) with JNCL. All patients were
      males, and the first symptoms appeared at the age of 6 years.
    explanation: >
      This primary biallelic-CLN6 case series directly documents juvenile onset
      and avoids relying on adult Kufs disease as the subtype anchor.
- name: CLN7 disease, juvenile onset
  description: >
    Juvenile MFSD8/CLN7 disease is a protracted branch distinct from the common
    late-infantile phenotype. Vision loss can begin around ten to twelve and a
    half years, with seizures following within several years.
  genes:
  - preferred_term: MFSD8
    term:
      id: hgnc:28486
      label: MFSD8
  evidence:
  - reference: PMID:42398224
    reference_title: "Clinical Symptoms in Late Infantile and Juvenile Onset Neuronal Ceroid Lipofuscinosis Type 7 (CLN7 Disease)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast, both participants with juvenile onset CLN7 disease had
      normal early development with vision loss as the initial symptom (ages
      10-12.5 years), followed by seizure onset within 4 years.
    explanation: >
      A longitudinal cohort directly distinguishes juvenile CLN7 from the
      late-infantile phenotype and supplies its onset sequence.
- name: CLN8 disease, juvenile-onset EPMR
  description: >
    The CLN8-related progressive epilepsy with intellectual disability (EPMR,
    Northern epilepsy) branch begins with generalized seizures between five and
    ten years, followed by progressive cognitive impairment. Unlike classic
    CLN3, visual loss is not its defining presentation.
  genes:
  - preferred_term: CLN8
    term:
      id: hgnc:2079
      label: CLN8
  evidence:
  - reference: PMID:10508524
    reference_title: "The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive epilepsy with mental retardation (EPMR, MIM 600143) was
      recently recognized as a new NCL subtype (CLN8). It is an autosomal
      recessive disorder characterized by onset of generalized seizures between
      5 and 10 years, and subsequent progressive mental retardation.
    explanation: >
      The positional-cloning study establishes both CLN8 identity and onset in
      the juvenile interval.
- name: CLN10 disease, late juvenile onset
  description: >
    A juvenile CTSD/CLN10 presentation begins around eight to twelve years and
    may present with ataxia, cognitive decline, and visual loss. It is an
    allelic presentation distinct from congenital and infantile CLN10 disease.
  genes:
  - preferred_term: CTSD
    term:
      id: hgnc:2529
      label: CTSD
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay
      Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual
      loss;
    explanation: >
      The classification table places CTSD/CLN10 in the late juvenile band and
      lists a distinct ataxia-cognitive-visual presentation.
- name: CLN12 disease, late juvenile onset
  description: >
    The ATP13A2/CLN12 juvenile NCL presentation begins in adolescence and is
    dominated at onset by rigidity and hypokinesia. It overlaps genetically
    with ATP13A2-related parkinsonism but is included here only at the
    NCL-pathology/onset altitude documented by the classification source.
  genes:
  - preferred_term: ATP13A2
    term:
      id: hgnc:30213
      label: ATP13A2
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "13–16 yrs CLN12 ATP13A2 NGS Rigidity, hypokinesia"
    explanation: >
      The review's childhood-NCL table explicitly places ATP13A2/CLN12 in the
      13–16-year juvenile-onset band.
  - reference: PMID:22388936
    reference_title: "Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a family with typical NCL pathology in which we performed exome
      sequencing and identified a single homozygous mutation in ATP13A2 that
      fully segregates with disease within the family.
    explanation: >
      The founding CLN12 family links recessive ATP13A2 directly to NCL
      pathology; the juvenile onset is supplied independently by the
      classification table.
classifications:
  lysosomal_storage_category:
    classification_value: neuronal ceroid lipofuscinosis
    notes: >
      The entry is an onset-defined neuronal ceroid lipofuscinosis umbrella
      with the same lysosomal ceroid-lipofuscin storage criterion as its
      genotype-specific members.
  icimd_category:
  - classification_value: neuronal_ceroid_lipofuscinosis
    notes: >
      ICIMD places the neuronal ceroid lipofuscinoses among disorders of
      complex-molecule degradation. This classification describes the shared
      disease family and does not collapse the supported juvenile genotypes.
notes: >
  Entity boundary. MONDO:0019262 describes a genetically heterogeneous group
  and carries an editor note that it is kept separate from CLN3 disease because
  it groups different CLNs. The current KB already models the same ontology
  altitude for adult NCL at MONDO:0019260. This record therefore mirrors that
  onset-grouping precedent and does not replace
  `Neuronal_Ceroid_Lipofuscinosis_3.yaml` (MONDO:0008767).

  Subtype guardrail. Each listed genotype has its own exact, independently
  verified human PMID supporting a juvenile presentation. CLN2, CLN7, and CLN8
  are limited here to their atypical juvenile/protracted presentations; their
  common late-infantile phenotypes are not relabeled. No additional CLN
  designation was added without direct juvenile-onset evidence.

  Genetic interpretation guardrail. Each modeled association is causative,
  germline, and recessive at the gene-disease level, but the cited literature
  does not establish a single penetrance estimate for juvenile presentation.
  Carrier-frequency estimates are therefore recorded only as ancestry-aware
  testing context, never converted into affected prevalence or penetrance.
  CLN6 intrafamilial observations demonstrate variable expressivity even with
  the same variant, while the recurrent CLN3 deletion requires explicit
  deletion/copy-number detection.

  Deep-research provenance. A sanctioned `claude_code` run on 2026-08-08
  (1,217 seconds, 11 web searches, 49 citations) was explicitly prompted for
  the genetically heterogeneous MONDO:0019262 entity and its distinction from
  MONDO:0008767. The automated named-entity preflight returned SKIP because
  this onset grouping has no single MONDO causal gene; manual review confirmed
  that the report remained anchored to MONDO:0019262 and assessed each
  candidate genotype separately. An earlier run that re-anchored the target to
  CLN3 disease failed that manual entity check and was discarded wholesale.
  Every PMID and evidence snippet used in this entry was then independently
  fetched and verified against the generated reference cache. The GeneReviews
  overview (PMID:20301601) is registered as a tagged orientation source, but
  its generated cache is metadata-only; no section-level evidence is attributed
  to that stub.
inheritance:
- name: Autosomal recessive inheritance
  description: >
    All nine genotype branches curated in this juvenile-onset umbrella are
    caused by biallelic pathogenic variants. The sole dominant NCL branch is
    adult-onset CLN4/DNAJC5 and is outside this entity.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "With the exception of CLN4 disease, all CLNs are recessive disorders."
    explanation: >
      The only dominant exception is the adult CLN4 branch; every juvenile
      genotype represented here is therefore recessive.
progression:
- phase: Classic CLN3 onset
  subtype: CLN3 disease, classic juvenile onset
  age_range: 4 to 7 years
  notes: >
    Rapid visual loss is usually followed by cognitive decline, behavioral
    problems, seizures, and later parkinsonian or other motor manifestations.
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The typical age of onset in CLN3 disease is between 4 years and 7 years,
      with insidious, but rapidly progressive, vision loss.
    explanation: >
      Defines the onset window and initial clinical feature for classic CLN3.
- phase: Juvenile CLN1 onset and progression
  subtype: CLN1 disease, juvenile onset
  age_range: 5 to 10 years
  notes: >
    Cognitive decline begins first; seizures, motor decline, and visual loss
    follow over later childhood and adolescence.
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The juvenile-onset form starts between the ages of 5 years and 10 years,
      with cognitive decline followed by seizures (7 to 17 years), motor decline
      (7 to 15 years), and vision loss (10 to 14 years).
    explanation: >
      Provides a genotype-specific juvenile CLN1 sequence rather than
      projecting the CLN3 sequence onto all subtypes.
- phase: Atypical juvenile CLN2 onset
  subtype: CLN2 disease, juvenile onset
  age_range: About or after 4 years
  notes: >
    Atypical TPP1/CLN2 cases begin later and may progress more slowly than
    classic late-infantile CLN2 disease.
  evidence:
  - reference: PMID:10191110
    reference_title: "Reevaluation of neuronal ceroid lipofuscinoses: atypical juvenile onset may be the result of CLN2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most of the typical and atypical probands had onset of symptoms about or
      after 4 years of age.
    explanation: >
      The molecularly evaluated juvenile cohort supplies the later CLN2 onset
      boundary without projecting the classic late-infantile trajectory.
- phase: Juvenile CLN5 onset
  subtype: CLN5 disease, juvenile onset
  age_range: 4 to 17 years
  notes: >
    The CLN5 onset distribution crosses clinical age bands, so this entry
    covers only CLN5 cases presenting in the juvenile interval.
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The age of onset in CLN5 disease varies from 4 to 17 years, with a mean
      of 5.6 years.
    explanation: Supports a genuine juvenile subset without relabeling every CLN5 case.
- phase: Late juvenile CLN6 onset
  subtype: CLN6 disease, late juvenile onset
  age_range: 8 to 12 years
  notes: >
    Myoclonic seizures and cognitive decline characterize the late juvenile
    CLN6 presentation represented in this onset grouping.
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay
      Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual
      loss;
    explanation: >
      The table places CLN6 in the 8–12-year row and gives its presenting
      manifestations.
- phase: Juvenile CLN7 onset
  subtype: CLN7 disease, juvenile onset
  age_range: 10 to 12.5 years
  notes: >
    Vision loss is the initial manifestation, followed by seizures within four
    years in the directly observed juvenile CLN7 cohort.
  evidence:
  - reference: PMID:42398224
    reference_title: "Clinical Symptoms in Late Infantile and Juvenile Onset Neuronal Ceroid Lipofuscinosis Type 7 (CLN7 Disease)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast, both participants with juvenile onset CLN7 disease had
      normal early development with vision loss as the initial symptom (ages
      10-12.5 years), followed by seizure onset within 4 years.
    explanation: >
      Provides the juvenile CLN7 onset window and its vision-first sequence.
- phase: Juvenile CLN8 EPMR onset
  subtype: CLN8 disease, juvenile-onset EPMR
  age_range: 5 to 10 years
  notes: >
    Generalized seizures precede progressive cognitive impairment; the course
    does not require the early visual-loss sequence typical of classic CLN3.
  evidence:
  - reference: PMID:10508524
    reference_title: "The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is an autosomal recessive disorder characterized by onset of
      generalized seizures between 5 and 10 years, and subsequent progressive
      mental retardation.
    explanation: >
      Directly defines the juvenile-onset sequence of the CLN8 EPMR branch.
- phase: Late juvenile CLN10 onset
  subtype: CLN10 disease, late juvenile onset
  age_range: 8 to 12 years
  notes: >
    Ataxia, cognitive decline, and visual loss characterize the late juvenile
    CTSD/CLN10 presentation represented in this onset grouping.
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay
      Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual
      loss;
    explanation: >
      The table places CTSD/CLN10 in the 8–12-year row and gives its presenting
      manifestations.
- phase: Late juvenile CLN12 onset
  subtype: CLN12 disease, late juvenile onset
  age_range: 13 to 16 years
  notes: >
    Rigidity and hypokinesia characterize the ATP13A2/CLN12 presentation in the
    oldest juvenile age stratum represented in this onset grouping.
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "13–16 yrs CLN12 ATP13A2 NGS Rigidity, hypokinesia"
    explanation: >
      The table places ATP13A2/CLN12 in the 13–16-year row and identifies its
      motor presentation.
genetic:
- name: CLN3
  subtype: CLN3 disease, classic juvenile onset
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  gene_term:
    preferred_term: CLN3
    term:
      id: hgnc:2074
      label: CLN3
  notes: >
    Biallelic CLN3 variants cause the classic juvenile NCL presentation. The
    common approximately 1-kb deletion accounts for most reported pathogenic
    alleles, but sequence and copy-number variants both require consideration.
    Population-genomic carrier estimates are ancestry-sensitive and are not
    penetrance estimates. Detailed CLN3 protein and variant mechanisms remain
    curated in `Neuronal_Ceroid_Lipofuscinosis_3.yaml`.
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      CLN3 disease is the classic juvenile-onset form of neuronal ceroid
      lipofuscinosis.
    explanation: Directly identifies the causal gene-defined classic juvenile branch.
  - reference: PMID:38500130
    reference_title: "The parent and family impact of CLN3 disease: an observational survey-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CLN3 disease (also known as CLN3 Batten disease or Juvenile Neuronal
      Ceroid Lipofuscinosis) is a rare pediatric neurodegenerative disorder
      caused by biallelic mutations in CLN3.
    explanation: >
      The clinical cohort directly supports biallelic CLN3 variants in the
      classic juvenile presentation.
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common sequence variant in CLN3 is a homozygous 1 kb deletion,
      accounting for approximately 85% of cases of JNCL.
    explanation: >
      Identifies the recurrent deletion that requires deletion/copy-number-aware
      molecular testing.
- name: PPT1
  subtype: CLN1 disease, juvenile onset
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  gene_term:
    preferred_term: PPT1
    term:
      id: hgnc:9325
      label: PPT1
  notes: >
    A subset of biallelic PPT1/CLN1 disease presents in the juvenile interval;
    classic infantile CLN1 remains outside this onset-defined entry. Finnish
    PPT1 carrier enrichment (about 1 in 75 in Finnish ExAC participants) must
    not be generalized across ancestries.
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A juvenile-onset form of CLN1 disease has also been described and has
      been referred to “juvenile neuronal ceroid lipofuscinosis with granular
      osmiophilic deposits.”
    explanation: Explicit evidence for the PPT1/CLN1 juvenile allelic presentation.
  - reference: PMID:17388982
    reference_title: "Juvenile-onset neuronal ceroid lipofuscinosis with infantile CLN1 mutation and palmitoyl-protein thioesterase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe a patient with juvenile-onset NCL phenotype with a new CLN1
      mutation and deficient PPT activity.
    explanation: Molecular and enzyme evidence directly supports juvenile PPT1/CLN1 disease.
  - reference: PMID:27553520
    reference_title: "Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Carrier frequency was dependent on ethnicity, with the highest (1/75)
      observed for PPT1 in the Finnish.
    explanation: >
      Supplies ancestry-specific carrier-frequency and founder-allele context;
      it does not establish the frequency of the juvenile presentation itself.
- name: TPP1
  subtype: CLN2 disease, juvenile onset
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  gene_term:
    preferred_term: TPP1
    term:
      id: hgnc:2073
      label: TPP1
  notes: >
    This association is restricted to atypical juvenile-onset CLN2 disease and
    does not relabel classic late-infantile TPP1 deficiency. TPP1 is among the
    more frequent NCL carrier genes in ancestry-adjusted US population-genomic
    estimates, but carrier frequency is neither penetrance nor the frequency of
    juvenile presentation.
  evidence:
  - reference: PMID:10191110
    reference_title: "Reevaluation of neuronal ceroid lipofuscinoses: atypical juvenile onset may be the result of CLN2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this group, we found probands with abundant curvilinear profiles in
      lysosomal storage material, deficiency of pepstatin-insensitive
      peptidase, and mutations in the CLN2 gene
    explanation: >
      The juvenile-onset cohort directly links CLN2 mutations, enzyme
      deficiency, and NCL storage pathology.
  - reference: PMID:27553520
    reference_title: "Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      PPT1, TPP1 and CLN3 carrier frequencies were found to be the highest of
      the NCLs, each at ~1/500.
    explanation: >
      Adds ancestry-stratified carrier context without treating carrier
      frequency as affected prevalence or penetrance.
- name: CLN5
  subtype: CLN5 disease, juvenile onset
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  gene_term:
    preferred_term: CLN5
    term:
      id: hgnc:2076
      label: CLN5
  notes: >
    CLN5 has a broad onset distribution; only juvenile-presenting cases belong
    to this onset umbrella.
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The age of onset in CLN5 disease varies from 4 to 17 years, with a mean
      of 5.6 years.
    explanation: The documented range spans juvenile age and supports this branch.
  - reference: PMID:20157158
    reference_title: "CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The age at disease onset in this cohort is predominantly juvenile rather
      than late infantile.
    explanation: Pathogenic CLN5 variants were found in a predominantly juvenile-onset cohort.
- name: CLN6
  subtype: CLN6 disease, late juvenile onset
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  gene_term:
    preferred_term: CLN6
    term:
      id: hgnc:2077
      label: CLN6
  notes: >
    This association is restricted to the late juvenile CLN6 presentation and
    does not absorb early variant-late-infantile or adult Kufs A disease.
    Juvenile CLN6 is phenotypically variable: biallelic variants can present
    without early visual loss, and even relatives with the same homozygous
    missense variant can differ in onset age and MRI severity.
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay
      Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual
      loss;
    explanation: Places CLN6 explicitly in the review's late juvenile row.
  - reference: PMID:22883287
    reference_title: "Mutation of the CLN6 gene in teenage-onset progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The affected gene is CLN6, previously known to underlie variant
      late-infantile and adult-onset neuronal ceroid lipofuscinoses.
    explanation: Genetic diagnosis identifies CLN6 in the teenage-onset family.
  - reference: PMID:34868216
    reference_title: "A Novel CLN6 Variant Associated With Juvenile Neuronal Ceroid Lipofuscinosis in Patients With Absence of Visual Loss as a Presenting Feature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report clinical and genetic findings of three patients from two
      Greek-Cypriot families (families 915 and 926) with JNCL. All patients were
      males, and the first symptoms appeared at the age of 6 years.
    explanation: >
      A primary molecular case series directly supports juvenile-onset CLN6
      disease rather than relying only on a classification review.
  - reference: PMID:35609511
    reference_title: "Juvenile-Onset Kufs Disease in a Chinese Consanguineous Family due to CLN6 Mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      patients with the same mutation showed different ages of onset and
      different levels of severity under MRI.
    explanation: >
      Intrafamilial variation with the same homozygous CLN6 variant documents
      variable expressivity; this does not convert the juvenile grouping into
      adult Kufs disease.
- name: MFSD8
  subtype: CLN7 disease, juvenile onset
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  gene_term:
    preferred_term: MFSD8
    term:
      id: hgnc:28486
      label: MFSD8
  notes: >
    This branch represents protracted juvenile CLN7; the common variant
    late-infantile MFSD8 phenotype remains outside this onset grouping.
  evidence:
  - reference: PMID:19201763
    reference_title: "Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In one patient with an in-frame amino acid substitution mutation in
      CLN7/MFSD8, the disease onset was later and the disease course less
      aggressive than in variant late-infantile NCL.
    explanation: >
      Human molecular evidence directly links MFSD8 to a later-onset,
      protracted NCL presentation.
  - reference: PMID:42398224
    reference_title: "Clinical Symptoms in Late Infantile and Juvenile Onset Neuronal Ceroid Lipofuscinosis Type 7 (CLN7 Disease)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We enrolled 5 participants with late infantile onset and 2 participants
      with juvenile onset CLN7 disease.
    explanation: >
      The longitudinal cohort independently confirms a juvenile CLN7 branch.
- name: CLN8
  subtype: CLN8 disease, juvenile-onset EPMR
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  gene_term:
    preferred_term: CLN8
    term:
      id: hgnc:2079
      label: CLN8
  notes: >
    The juvenile EPMR/Northern-epilepsy presentation is distinct from severe
    variant late-infantile CLN8 disease.
  evidence:
  - reference: PMID:10508524
    reference_title: "The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we report the positional cloning of a novel gene, CLN8, which is
      mutated in EPMR.
    explanation: >
      The positional-cloning study directly establishes CLN8 as the EPMR gene.
- name: CTSD
  subtype: CLN10 disease, late juvenile onset
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  gene_term:
    preferred_term: CTSD
    term:
      id: hgnc:2529
      label: CTSD
  notes: >
    The juvenile CTSD/CLN10 presentation is allelic to, but clinically distinct
    from, congenital and infantile CTSD deficiency.
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Late 8–12 yrs CLN6 CLN10 CLN6 CLN10/CTSD NGS NGS enzymatic assay
      Myoclonic seizures, cognitive decline; ataxia, cognitive decline, visual
      loss;
    explanation: Places CTSD/CLN10 explicitly in the review's late juvenile row.
- name: ATP13A2
  subtype: CLN12 disease, late juvenile onset
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  gene_term:
    preferred_term: ATP13A2
    term:
      id: hgnc:30213
      label: ATP13A2
  notes: >
    ATP13A2 has an overlapping parkinsonism disease spectrum. It is represented
    here only where the clinical classification assigns it to CLN12 with
    juvenile onset and NCL pathology.
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "13–16 yrs CLN12 ATP13A2 NGS Rigidity, hypokinesia"
    explanation: Explicitly identifies ATP13A2 as the CLN12 late juvenile genotype.
  - reference: PMID:22388936
    reference_title: "Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a family with typical NCL pathology in which we performed exome
      sequencing and identified a single homozygous mutation in ATP13A2 that
      fully segregates with disease within the family.
    explanation: Direct human genetic and pathological evidence for ATP13A2-related NCL.
pathophysiology:
- name: PPT1 lysosomal thioesterase deficiency
  subtypes:
  - CLN1 disease, juvenile onset
  biological_scale: MOLECULAR
  description: >
    Biallelic PPT1 lesions can produce deficient palmitoyl-protein thioesterase
    activity in juvenile-onset CLN1. The molecular steps between this proximal
    enzyme lesion and storage are not collapsed into a guessed substrate chain.
  gene:
    preferred_term: PPT1
    term:
      id: hgnc:9325
      label: PPT1
  molecular_functions:
  - preferred_term: palmitoyl-protein thioesterase activity
    term:
      id: GO:0008474
      label: palmitoyl-(protein) hydrolase activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:17388982
    reference_title: "Juvenile-onset neuronal ceroid lipofuscinosis with infantile CLN1 mutation and palmitoyl-protein thioesterase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe a patient with juvenile-onset NCL phenotype with a new CLN1
      mutation and deficient PPT activity.
    explanation: Direct molecular and biochemical evidence for the proximal juvenile CLN1 lesion.
  downstream:
  - target: Lysosomal Ceroid-Lipofuscin Storage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >
      PPT1 deficiency converges on the NCL storage phenotype, but omitted
      substrate and trafficking steps remain incompletely resolved.
- name: TPP1 lysosomal peptidase deficiency
  subtypes:
  - CLN2 disease, juvenile onset
  biological_scale: MOLECULAR
  description: >
    Atypical juvenile CLN2 is a biallelic TPP1 branch with deficient
    pepstatin-insensitive peptidase activity and CLN2 mutations.
  gene:
    preferred_term: TPP1
    term:
      id: hgnc:2073
      label: TPP1
  molecular_functions:
  - preferred_term: pepstatin-insensitive tripeptidyl-peptidase I activity
    term:
      id: GO:0008240
      label: tripeptidyl-peptidase activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:10191110
    reference_title: "Reevaluation of neuronal ceroid lipofuscinoses: atypical juvenile onset may be the result of CLN2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this group, we found probands with abundant curvilinear profiles in
      lysosomal storage material, deficiency of pepstatin-insensitive
      peptidase, and mutations in the CLN2 gene
    explanation: Directly links the juvenile cohort's TPP1 lesion to its storage phenotype.
  downstream:
  - target: Lysosomal Ceroid-Lipofuscin Storage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Deficient TPP1 lysosomal proteolysis precedes the shared storage node.
- name: CLN3 lysosomal transmembrane protein dysfunction
  subtypes:
  - CLN3 disease, classic juvenile onset
  biological_scale: MOLECULAR
  description: >
    Classic juvenile CLN3 begins with biallelic lesions of a lysosomal
    transmembrane protein whose primary function remains unresolved; the graph
    therefore does not invent a direct molecular activity.
  gene:
    preferred_term: CLN3
    term:
      id: hgnc:2074
      label: CLN3
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The CLN3 protein is a lysosomal transmembrane protein of unknown function."
    explanation: Establishes localization while explicitly preserving functional uncertainty.
  downstream:
  - target: Lysosomal Ceroid-Lipofuscin Storage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: CLN3 dysfunction converges on fingerprint-type lysosomal storage through unresolved intermediates.
- name: CLN5 soluble lysosomal protein dysfunction
  subtypes:
  - CLN5 disease, juvenile onset
  biological_scale: MOLECULAR
  description: >
    Juvenile CLN5 begins with biallelic lesions of a soluble lysosomal
    glycoprotein. Its proximal biochemical function is left unresolved at this
    evidence altitude.
  gene:
    preferred_term: CLN5
    term:
      id: hgnc:2076
      label: CLN5
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The CLN5 protein is a soluble lysosomal glycoprotein of unknown function."
    explanation: Establishes lysosomal localization without overstating an unknown function.
  downstream:
  - target: Lysosomal Ceroid-Lipofuscin Storage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: CLN5 dysfunction converges on storage through incompletely resolved intermediates.
- name: CLN6 ER transmembrane protein dysfunction
  subtypes:
  - CLN6 disease, late juvenile onset
  biological_scale: MOLECULAR
  description: >
    Juvenile CLN6 begins with biallelic lesions of an endoplasmic-reticulum
    transmembrane protein involved in lysosomal function and acidification.
  gene:
    preferred_term: CLN6
    term:
      id: hgnc:2077
      label: CLN6
  evidence:
  - reference: PMID:34868216
    reference_title: "A Novel CLN6 Variant Associated With Juvenile Neuronal Ceroid Lipofuscinosis in Patients With Absence of Visual Loss as a Presenting Feature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CLN6 encodes an endoplasmic reticulum non-glycosylated transmembrane
      protein, which is involved in lysosomal acidification.
    explanation: Supplies a proximal cellular context from a juvenile CLN6 case series.
  downstream:
  - target: Lysosomal Ceroid-Lipofuscin Storage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: ER-localized CLN6 dysfunction impairs lysosomal homeostasis before storage accumulates.
- name: MFSD8 lysosomal membrane transporter dysfunction
  subtypes:
  - CLN7 disease, juvenile onset
  biological_scale: MOLECULAR
  description: >
    Juvenile CLN7 begins with biallelic MFSD8 lesions affecting a lysosomal
    membrane member of the major facilitator transporter superfamily.
  gene:
    preferred_term: MFSD8
    term:
      id: hgnc:28486
      label: MFSD8
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The CLN7 protein is a lysosomal membrane protein that belongs to the
      “major facilitator” superfamily of transporter proteins.
    explanation: Establishes the proximal protein class and lysosomal localization.
  downstream:
  - target: Lysosomal Ceroid-Lipofuscin Storage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: MFSD8 transporter dysfunction converges on storage through unresolved cargo steps.
- name: CLN8 ER transmembrane protein dysfunction
  subtypes:
  - CLN8 disease, juvenile-onset EPMR
  biological_scale: MOLECULAR
  description: >
    Juvenile CLN8 EPMR begins with biallelic lesions of an endoplasmic-reticulum
    transmembrane protein; the source does not establish a single direct
    substrate mechanism.
  gene:
    preferred_term: CLN8
    term:
      id: hgnc:2079
      label: CLN8
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      CLN8 disease is due to mutations in a transmembrane protein of the
      endoplasmic reticulum of unknown function.
    explanation: Establishes ER localization and explicitly bounded functional uncertainty.
  downstream:
  - target: Lysosomal Ceroid-Lipofuscin Storage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: CLN8 dysfunction converges on NCL storage through incompletely known intermediates.
- name: CTSD lysosomal protease deficiency
  subtypes:
  - CLN10 disease, late juvenile onset
  biological_scale: MOLECULAR
  description: >
    Juvenile CLN10 begins with biallelic CTSD lesions causing cathepsin-D
    deficiency, a lysosomal-enzyme branch distinct from membrane-protein NCLs.
  gene:
    preferred_term: CTSD
    term:
      id: hgnc:2529
      label: CTSD
  molecular_functions:
  - preferred_term: cathepsin D activity
    term:
      id: GO:0004190
      label: aspartic-type endopeptidase activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  notes: >
    PMID:25298308 (Hersheson et al.) is the primary molecular case series for
    this presentation but has no quotable abstract in the reference cache
    (title/author metadata only), so it is not cited as a snippet-level
    evidence item here; see PMID:35359645 above for the CTSD/CLN10
    late-juvenile classification.
  downstream:
  - target: Lysosomal Ceroid-Lipofuscin Storage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Cathepsin-D deficiency precedes storage through incompletely defined substrates.
- name: ATP13A2 transmembrane protein dysfunction
  subtypes:
  - CLN12 disease, late juvenile onset
  biological_scale: MOLECULAR
  description: >
    The CLN12 branch begins with a homozygous ATP13A2 lesion affecting a
    transmembrane protein and is retained here only where NCL pathology was
    demonstrated.
  gene:
    preferred_term: ATP13A2
    term:
      id: hgnc:30213
      label: ATP13A2
  evidence:
  - reference: PMID:26026925
    reference_title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      many transmembrane proteins with different subcellular locations (CLN3,
      CLN6, CLN7, CLN8, CLN12).
    explanation: Classifies CLN12 among transmembrane-protein NCL lesions.
  - reference: PMID:22388936
    reference_title: "Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a family with typical NCL pathology in which we performed exome
      sequencing and identified a single homozygous mutation in ATP13A2 that
      fully segregates with disease within the family.
    explanation: Directly anchors the ATP13A2 lesion to human NCL pathology.
  downstream:
  - target: Lysosomal Ceroid-Lipofuscin Storage
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: ATP13A2 dysfunction converges on NCL storage through unresolved intermediates.
- name: Lysosomal Ceroid-Lipofuscin Storage
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  biological_scale: CELLULAR
  description: >
    The supported juvenile genotypes disrupt different lysosomal or
    endomembrane proteins, but converge at the disease-family level on
    intracellular ceroid-lipofuscin storage and progressive neurodegeneration.
    The onset umbrella does not assert one gene-specific upstream mechanism for
    all nine branches.
  genes:
  - preferred_term: CLN3
    term:
      id: hgnc:2074
      label: CLN3
  - preferred_term: PPT1
    term:
      id: hgnc:9325
      label: PPT1
  - preferred_term: TPP1
    term:
      id: hgnc:2073
      label: TPP1
  - preferred_term: CLN5
    term:
      id: hgnc:2076
      label: CLN5
  - preferred_term: CLN6
    term:
      id: hgnc:2077
      label: CLN6
  - preferred_term: MFSD8
    term:
      id: hgnc:28486
      label: MFSD8
  - preferred_term: CLN8
    term:
      id: hgnc:2079
      label: CLN8
  - preferred_term: CTSD
    term:
      id: hgnc:2529
      label: CTSD
  - preferred_term: ATP13A2
    term:
      id: hgnc:30213
      label: ATP13A2
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: lysosomal transport
    modifier: DYSREGULATED
    term:
      id: GO:0007041
      label: lysosomal transport
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The neuronal ceroid lipofuscinoses represent a group of disorders
      characterized by neurodegeneration and intracellular accumulation of an
      auto-fluorescent lipopigment (ceroid lipofuscin).
    explanation: >
      Defines the storage-neurodegeneration convergence modeled at the umbrella
      level.
  downstream:
  - target: Visual impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >
      Retinal storage and degeneration produce progressive visual impairment
      in the juvenile NCL clinical spectrum, although timing varies by genotype.
    evidence:
    - reference: PMID:23838030
      reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        These 4 primary forms have common features of a neurodegenerative
        course with epilepsy, dementia, a movement disorder, and retinal
        degeneration (except adult-onset neuronal ceroid lipofuscinosis), and
        storage of ceroid lipofuscin in neurons.
      explanation: Links the non-adult NCL storage phenotype with retinal degeneration.
  - target: Cognitive impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Progressive neurodegeneration produces cognitive decline and dementia.
    evidence:
    - reference: PMID:23838030
      reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        These 4 primary forms have common features of a neurodegenerative
        course with epilepsy, dementia, a movement disorder, and retinal
        degeneration (except adult-onset neuronal ceroid lipofuscinosis), and
        storage of ceroid lipofuscin in neurons.
      explanation: Connects the shared neurodegenerative course to dementia.
  - target: Seizure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Progressive neuronal dysfunction contributes to epilepsy and seizures.
    evidence:
    - reference: PMID:23838030
      reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        These 4 primary forms have common features of a neurodegenerative
        course with epilepsy, dementia, a movement disorder, and retinal
        degeneration (except adult-onset neuronal ceroid lipofuscinosis), and
        storage of ceroid lipofuscin in neurons.
      explanation: Identifies epilepsy within the shared NCL neurodegenerative course.
  - target: Motor deterioration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Progressive NCL neurodegeneration produces worsening motor disability.
    evidence:
    - reference: PMID:23838030
      reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        These 4 primary forms have common features of a neurodegenerative
        course with epilepsy, dementia, a movement disorder, and retinal
        degeneration (except adult-onset neuronal ceroid lipofuscinosis), and
        storage of ceroid lipofuscin in neurons.
      explanation: Identifies movement disorder within the shared NCL course.
phenotypes:
- name: Visual impairment
  description: >
    Progressive visual loss is often the presenting feature of classic CLN3
    and is also documented in juvenile CLN1, CLN5, CLN7, and CLN10. Its timing
    is not uniform across the genetically heterogeneous umbrella, and early
    visual loss is not required in CLN8 EPMR.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      He described a juvenile-onset disorder with blindness and progressive
      dementia.
    explanation: The historical juvenile NCL description establishes visual loss as a defining feature.
- name: Cognitive impairment
  description: >
    Cognitive slowing and decline are central juvenile NCL manifestations,
    although they follow vision loss in classic CLN3 and may precede it in
    juvenile CLN1.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      He described a juvenile-onset disorder with blindness and progressive
      dementia.
    explanation: The classic juvenile phenotype explicitly includes progressive dementia.
- name: Seizure
  description: >
    Epileptic seizures occur across the juvenile NCL spectrum, but their onset
    and semiology vary by genotype; myoclonic seizures are especially prominent
    in later juvenile CLN6, while generalized seizures define CLN8 EPMR onset.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      These 4 primary forms have common features of a neurodegenerative course
      with epilepsy, dementia, a movement disorder, and retinal degeneration
      (except adult-onset neuronal ceroid lipofuscinosis), and storage of ceroid
      lipofuscin in neurons.
    explanation: Identifies epilepsy as a shared clinical feature of the classic NCL forms.
- name: Motor deterioration
  description: >
    Progressive motor decline may include ataxia, parkinsonism, rigidity,
    hypokinesia, or loss of ambulation depending on genotype and disease stage.
  phenotype_term:
    preferred_term: Motor deterioration
    term:
      id: HP:0002333
      label: Motor deterioration
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      These 4 primary forms have common features of a neurodegenerative course
      with epilepsy, dementia, a movement disorder, and retinal degeneration
      (except adult-onset neuronal ceroid lipofuscinosis), and storage of ceroid
      lipofuscin in neurons.
    explanation: Supports progressive movement disorder at the shared disease-family level.
- name: Atypical behavior
  description: >
    Behavioral problems are characteristic early features in classic juvenile
    CLN3 and juvenile CLN5, but are not projected onto every genotype in this
    umbrella.
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Behavioral problems at onset characterize CLN3 and CLN5 diseases
    explanation: Restricts the behavior assertion to the two juvenile branches named by the review.
- name: Retinal degeneration
  description: >
    Retinal degeneration underlies progressive visual loss in classic CLN3 and
    several other childhood NCL branches, while early retinal disease is not
    required in CLN8 EPMR or every juvenile CLN6 case.
  phenotype_term:
    preferred_term: Retinal degeneration
    term:
      id: HP:0000546
      label: Retinal degeneration
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      These 4 primary forms have common features of a neurodegenerative course
      with epilepsy, dementia, a movement disorder, and retinal degeneration
      (except adult-onset neuronal ceroid lipofuscinosis), and storage of ceroid
      lipofuscin in neurons.
    explanation: Directly identifies retinal degeneration within childhood NCL phenotypes.
- name: Ataxia
  description: >
    Ataxia is prominent in several non-CLN3 juvenile branches, including CLN5,
    CLN6, and CLN10, but its timing varies.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Clinical features include psychomotor regression, ataxia, myoclonic
      epilepsy, and visual failure, which may be a presenting sign.
    explanation: Explicitly supports ataxia in the juvenile-age-spanning CLN5 branch.
- name: Myoclonus
  description: >
    Myoclonus may accompany epilepsy and motor decline, particularly in CLN2,
    CLN5, and CLN6 presentations; it is not asserted as universal.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Ataxia, myoclonus, and, ultimately, spastic quadriparesis follow. The
      myoclonus may be severe and refractory to treatment.
    explanation: Directly documents myoclonus in CLN2 disease.
- name: Dementia
  description: >
    Progressive dementia is part of the historic juvenile NCL phenotype and
    can emerge after early visual, behavioral, or seizure manifestations.
  phenotype_term:
    preferred_term: Dementia
    term:
      id: HP:0000726
      label: Dementia
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "He described a juvenile-onset disorder with blindness and progressive dementia."
    explanation: Directly supports dementia in the historical juvenile phenotype.
- name: Parkinsonism
  description: >
    Parkinsonism is a later motor manifestation in many classic CLN3 patients
    and also helps contextualize the ATP13A2/CLN12 branch.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In most patients, parkinsonism develops (11 to 13 years of age)."
    explanation: Provides a genotype-specific later CLN3 motor phenotype.
- name: Developmental regression
  description: >
    Psychomotor or developmental regression is especially documented in CLN5
    and TPP1/CLN2 disease; the umbrella does not impose it on every branch.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Clinical features include psychomotor regression, ataxia, myoclonic
      epilepsy, and visual failure, which may be a presenting sign.
    explanation: Explicitly supports regression in the juvenile-age-spanning CLN5 branch.
biochemical:
- name: Autofluorescent ceroid-lipofuscin storage
  presence: INCREASED
  context: >
    Intracellular autofluorescent ceroid-lipofuscin is the defining storage
    readout across NCLs. Ultrastructural morphology differs by genotype, so no
    single inclusion pattern is asserted for the entire juvenile umbrella.
  readouts:
  - target: Lysosomal Ceroid-Lipofuscin Storage
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Increased autofluorescent lipopigment reports the shared storage node.
    evidence:
    - reference: PMID:23838030
      reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The neuronal ceroid lipofuscinoses represent a group of disorders
        characterized by neurodegeneration and intracellular accumulation of an
        auto-fluorescent lipopigment (ceroid lipofuscin).
      explanation: Defines the diagnostic storage material.
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The neuronal ceroid lipofuscinoses represent a group of disorders
      characterized by neurodegeneration and intracellular accumulation of an
      auto-fluorescent lipopigment (ceroid lipofuscin).
    explanation: Supports increased intracellular ceroid-lipofuscin as the shared readout.
diagnosis:
- name: Broad molecular panel with deletion and copy-number analysis
  description: >
    A child with a juvenile NCL phenotype should undergo molecular testing
    broad enough to distinguish the supported CLN3, PPT1, TPP1, CLN5, CLN6,
    MFSD8, CLN8, CTSD, and ATP13A2 branches. Age and presenting sequence guide
    interpretation but do not reliably identify the genotype by themselves.
    The assay must include deletion/copy-number detection, because the common
    CLN3 lesion and other multi-exon deletions can be missed by sequence-only
    pipelines.
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Most experts in neuronal ceroid lipofuscinosis now recommend primary
      classification by gene (or protein), with secondary classification by
      age of onset and clinical features.
    explanation: Supports gene-first classification for an onset-defined clinical presentation.
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common sequence variant in CLN3 is a homozygous 1 kb deletion,
      accounting for approximately 85% of cases of JNCL.
    explanation: >
      A recurrent deletion in the classic branch makes deletion/copy-number
      coverage an essential part of the molecular workflow.
- name: Lysosomal enzyme assay triage
  description: >
    PPT1, TPP1, and CTSD activity assays provide a rapid biochemical route into
    the CLN1, CLN2, and CLN10 branches, respectively. Enzyme results complement
    rather than replace biallelic molecular confirmation.
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      enzymatic assays became available for four lysosomal enzym es: CTSD, CTSF
      , PPT1, and TPP1
    explanation: >
      The diagnostic review identifies CTSD, PPT1, and TPP1 among the lysosomal
      enzymes with available biochemical assays; the spacing reflects the
      source PDF extraction.
- name: Peripheral blood film and storage-inclusion screening
  description: >
    In a child with rapid bilateral visual loss suggestive of classic CLN3,
    vacuolated lymphocytes on peripheral blood film provide a rapid screening
    clue and fingerprint lysosomal inclusions can be demonstrated by electron
    microscopy. These findings do not identify every non-CLN3 juvenile branch.
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Blood film microscopy performed for all 8 patients demonstrated
      vacuolated lymphocytes. Electron microscopy was done sequentially in 7
      patients, and all showed lysosomal (fingerprint) inclusions.
    explanation: >
      Directly supports both screening steps in a molecularly confirmed CLN3
      juvenile cohort.
- name: Retinal electrophysiology and multimodal imaging
  description: >
    Full-field electroretinography, fundus autofluorescence, and OCT can expose
    severe generalized retinal and macular dysfunction when rapid visual loss
    raises classic CLN3 suspicion. These are phenotype-directed adjuncts, not a
    gene-independent confirmation test for the whole umbrella.
  evidence:
  - reference: PMID:31926949
    reference_title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Full-field and flash ERGs were recorded in all patients under photopic and
      scotopic conditions. Cases 1, 2, 4, and 5 had undetectable ERGs, in
      keeping with severe rod and cone photoreceptor dysfunction
    explanation: Demonstrates a severe electrophysiologic retinal signature in CLN3 disease.
  - reference: PMID:36964447
    reference_title: "Early recognition of CLN3 disease facilitated by visual electrophysiology and multimodal imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Best corrected visual acuity (BCVA), electroretinogram (ERG), ultra-widefield
      (UWF) fundus photography and fundus autofluorescence (FAF), and optical
      coherence tomography (OCT) studies were undertaken.
    explanation: Independently documents the multimodal retinal assessment set in CLN3 disease.
- name: Ultrastructural storage-pattern analysis
  description: >
    Electron microscopy can classify granular osmiophilic, curvilinear,
    fingerprint, or rectilinear storage patterns and thereby focus biochemical
    and molecular testing. Overlap between newer genotype-defined NCLs means
    ultrastructure remains supportive rather than definitive.
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The distinctive ultrastructural patterns are granular osmiophilic deposits
      in infantile neuronal ceroid lipofuscinosis, curvilinear profiles in
      late-infantile neuronal ceroid lipofuscinosis, fingerprint bodies in
      juvenile neuronal ceroid lipofuscinosis, and rectilinear profiles in
      adult-onset neuronal ceroid lipofuscinosis.
    explanation: >
      Defines the classic electron-microscopy patterns while the adjacent review
      text cautions that newer forms overlap.
treatments:
- name: Supportive care
  description: >
    Management is genotype- and symptom-specific and remains primarily
    supportive. This onset umbrella does not extrapolate a therapy studied in
    CLN3 or another single genotype to every juvenile NCL branch.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "palliative care and symptomatic treatments which are still the main therapeutic interventions."
    explanation: Supports supportive and palliative management across NCLs.
- name: Antiseizure pharmacotherapy
  description: >
    Antiseizure medication is used to reduce seizure burden. Drug choice must
    account for genotype and seizure semiology, and treatment is not represented
    as disease-modifying. Agents known to exacerbate myoclonus should be
    avoided; the cited clinical review specifically cautions against
    carbamazepine.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: anticonvulsant agent
      term:
        id: NCIT:C264
        label: Anticonvulsant Agent
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "there is consensus that medications for epilepsy are used to alleviate seizure burden"
    explanation: Supports symptomatic seizure-burden reduction rather than cure.
  - reference: PMID:35359645
    reference_title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "those which are known to exacerbate myoclonus are best avoided. The most commonly used anti-seizure medications are valproate, levetiracetam and the benzodiazepines in varying combinati ons. Carbamazepine is avoided."  # codespell:ignore-line
    explanation: >
      Supports the narrow prescribing caution; no uncited list of additional
      drugs is inferred from it.
- name: Cerliponase alfa for the TPP1/CLN2 branch
  description: >
    Intracerebroventricular recombinant human TPP1 enzyme replacement targets
    the proximal enzyme lesion in CLN2 disease and slows motor-language decline.
    The efficacy trial summarized by the source focused on late-infantile CLN2,
    not a juvenile-onset-stratified cohort; use for atypical juvenile CLN2
    therefore requires genotype confirmation and specialist assessment rather
    than extrapolation to every juvenile NCL branch.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: enzyme replacement therapy
    term:
      id: NCIT:C16221
      label: Protein Replacement Therapy
  target_mechanisms:
  - target: TPP1 lysosomal peptidase deficiency
    treatment_effect: RESTORES
    description: Cerliponase alfa replaces the deficient TPP1 enzyme in the CLN2 branch.
    evidence:
    - reference: PMID:31884868
      reference_title: "Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Cerliponase alfa is recombinant human tripeptidyl peptidase 1 enzyme
        replacement therapy.
      explanation: Directly identifies the replacement protein and proximal treatment target.
  evidence:
  - reference: PMID:31884868
    reference_title: "Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment with intracerebroventricular cerliponase alfa resulted in slower
      decline of motor and language functions compared with natural history
      controls.
    explanation: Supplies the clinical efficacy signal while the description preserves onset-scope limits.
  - reference: PMID:31884868
    reference_title: "Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cerliponase alfa is the first therapy for neuronal ceroid lipofuscinosis
      type 2 that targets the disease etiology.
    explanation: Supports the etiologic, branch-specific treatment classification.
discussions:
- discussion_id: juvenile_ncl_grouping_vs_cln3_identity
  prompt: Is juvenile neuronal ceroid lipofuscinosis identical to CLN3 disease?
  kind: CONTROVERSY
  status: RESOLVED
  rationale: >
    Historical and much modern clinical literature uses JNCL as a synonym for
    classic CLN3 disease. MONDO:0019262, however, explicitly preserves a
    separate genetically heterogeneous onset grouping, and the clinical
    classification literature documents juvenile presentations outside CLN3.
  resolution_note: >
    Curate MONDO:0019262 as an onset grouping alongside the existing CLN3
    genotype entry. Keep CLN3-specific variants, molecular mechanisms, trials,
    and natural history in `Neuronal_Ceroid_Lipofuscinosis_3.yaml`.
  evidence:
  - reference: PMID:23838030
    reference_title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A juvenile-onset form of CLN1 disease has also been described and has
      been referred to “juvenile neuronal ceroid lipofuscinosis with granular
      osmiophilic deposits.”
    explanation: Demonstrates that juvenile NCL terminology is not exclusive to CLN3.
datasets: []
references:
- reference: PMID:9151309
  title: "Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures."
- reference: PMID:10191110
  title: "Reevaluation of neuronal ceroid lipofuscinoses: atypical juvenile onset may be the result of CLN2 mutations."
- reference: PMID:10508524
  title: "The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8."
- reference: PMID:17388982
  title: "Juvenile-onset neuronal ceroid lipofuscinosis with infantile CLN1 mutation and palmitoyl-protein thioesterase deficiency."
- reference: PMID:19201763
  title: "Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis."
- reference: PMID:20157158
  title: "CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL."
- reference: PMID:20301601
  title: "Neuronal Ceroid Lipofuscinoses Overview."
  tags:
  - GeneReviews
- reference: PMID:22388936
  title: "Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis."
- reference: PMID:22883287
  title: "Mutation of the CLN6 gene in teenage-onset progressive myoclonus epilepsy."
- reference: PMID:23838030
  title: "Classification and natural history of the neuronal ceroid lipofuscinoses."
- reference: PMID:25298308
  title: "Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology."
- reference: PMID:26026925
  title: "Genetics of the neuronal ceroid lipofuscinoses (Batten disease)."
- reference: PMID:27553520
  title: "Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis."
- reference: PMID:31884868
  title: "Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2."
- reference: PMID:31926949
  title: "Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy."
- reference: PMID:34868216
  title: "A Novel CLN6 Variant Associated With Juvenile Neuronal Ceroid Lipofuscinosis in Patients With Absence of Visual Loss as a Presenting Feature."
- reference: PMID:35359645
  title: "Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview."
- reference: PMID:35609511
  title: "Juvenile-Onset Kufs Disease in a Chinese Consanguineous Family due to CLN6 Mutation."
- reference: PMID:36964447
  title: "Early recognition of CLN3 disease facilitated by visual electrophysiology and multimodal imaging."
- reference: PMID:38500130
  title: "The parent and family impact of CLN3 disease: an observational survey-based study."
- reference: PMID:42398224
  title: "Clinical Symptoms in Late Infantile and Juvenile Onset Neuronal Ceroid Lipofuscinosis Type 7 (CLN7 Disease)."
📚

References & Deep Research

References

21
PMID:9151309
Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures.
No top-level findings curated for this source.
PMID:10191110
Reevaluation of neuronal ceroid lipofuscinoses: atypical juvenile onset may be the result of CLN2 mutations.
No top-level findings curated for this source.
PMID:10508524
The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8.
No top-level findings curated for this source.
PMID:17388982
Juvenile-onset neuronal ceroid lipofuscinosis with infantile CLN1 mutation and palmitoyl-protein thioesterase deficiency.
No top-level findings curated for this source.
PMID:19201763
Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis.
No top-level findings curated for this source.
PMID:20157158
CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL.
No top-level findings curated for this source.
PMID:20301601
Neuronal Ceroid Lipofuscinoses Overview.
No top-level findings curated for this source.
PMID:22388936
Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.
No top-level findings curated for this source.
PMID:22883287
Mutation of the CLN6 gene in teenage-onset progressive myoclonus epilepsy.
No top-level findings curated for this source.
PMID:23838030
Classification and natural history of the neuronal ceroid lipofuscinoses.
No top-level findings curated for this source.
PMID:25298308
Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology.
No top-level findings curated for this source.
PMID:26026925
Genetics of the neuronal ceroid lipofuscinoses (Batten disease).
No top-level findings curated for this source.
PMID:27553520
Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis.
No top-level findings curated for this source.
PMID:31884868
Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2.
No top-level findings curated for this source.
PMID:31926949
Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy.
No top-level findings curated for this source.
PMID:34868216
A Novel CLN6 Variant Associated With Juvenile Neuronal Ceroid Lipofuscinosis in Patients With Absence of Visual Loss as a Presenting Feature.
No top-level findings curated for this source.
PMID:35359645
Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview.
No top-level findings curated for this source.
PMID:35609511
Juvenile-Onset Kufs Disease in a Chinese Consanguineous Family due to CLN6 Mutation.
No top-level findings curated for this source.
PMID:36964447
Early recognition of CLN3 disease facilitated by visual electrophysiology and multimodal imaging.
No top-level findings curated for this source.
PMID:38500130
The parent and family impact of CLN3 disease: an observational survey-based study.
No top-level findings curated for this source.
PMID:42398224
Clinical Symptoms in Late Infantile and Juvenile Onset Neuronal Ceroid Lipofuscinosis Type 7 (CLN7 Disease).
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
1. Disease Information
claude-haiku-4-5-20251001, claude-opus-5 49 citations 2026-08-08T18:30:22.953577

1. Disease Information

1.1 Overview

The neuronal ceroid lipofuscinoses (NCLs) are a group of inherited, mostly autosomal recessive, lysosomal-storage neurodegenerative disorders unified by the intracellular accumulation of autofluorescent, PAS- and Sudan-black-positive "ceroid-lipofuscin" storage material in neurons and extraneural tissue. They have been subclassified since Santavuori's era along two orthogonal axes:

  1. Age of onset — congenital, infantile, late-infantile, juvenile, adult (Kufs)
  2. Causal gene — CLN1–CLN8, CLN10–CLN14 (CLN9 is withdrawn; see §4.6)

MONDO:0019262 is a class on the first axis. It denotes the cohort of NCL patients whose first symptom appears in the juvenile window — conventionally ~5–10 years of age (some authors use 4–10 or extend to early adolescence) — regardless of which gene is mutated.

The clinical gestalt of the juvenile window is distinctive and largely gene-independent:

  • Vision is usually the herald symptom. A previously normal school-age child presents to an ophthalmologist with rapidly progressive central visual loss and a pigmentary retinopathy/bull's-eye maculopathy. Frequent initial misdiagnoses are Stargardt disease, retinitis pigmentosa, or cone–rod dystrophy.
  • Cognitive and behavioural decline follows within 1–3 years — school failure, then frank dementia, often with a striking psychiatric prodrome (anxiety, psychosis, hallucinations) in the CLN3 subgroup.
  • Seizures (generalised tonic-clonic and myoclonic) begin typically age 8–13.
  • Motor decline — extrapyramidal (parkinsonism, dystonia, rigidity) plus cerebellar ataxia and pyramidal signs — leads to loss of ambulation in the second decade.
  • Death in the late second to third decade for CLN3; earlier or later for other genotypes.

The critical exceptions to this gestalt are diagnostically load-bearing and are detailed gene-by-gene in §4: CLN8/EPMR ("Northern epilepsy") presents with seizures and no visual failure, and some CLN6 juvenile patients present with ataxia/spasticity and explicitly no visual loss.

1.2 Key identifiers

Resource Identifier Note
MONDO MONDO:0019262 The target entity. Definition and editor note quoted above.
Orphanet ORPHA:79264 Primary xref; the Orphanet grouping "Juvenile neuronal ceroid lipofuscinosis".
DOID DOID:0050756
GARD GARD:0004938
MedDRA MedDRA:10052073
SNOMED CT SCTID:61663001
ICD-11 Foundation icd11.foundation:1716107919
NANDO NANDO:1200154, NANDO:2201243 Japanese rare-disease nomenclature
ICD-10 E75.4 (group-level, "Neuronal ceroid lipofuscinosis") ⚠️ Group-level code shared with all NCLs; not juvenile-specific. Not independently re-verified this session.
OMIM none ⚠️ Important: MONDO:0019262 has no OMIM xref, because OMIM is organised gene-first. Every OMIM number in this space (204200, 256730, 204500, 256731, 601780, 610951, 600143, 610127, 614706, 606693, 615362, 611726) belongs to a gene-defined entity, not to the onset grouping. Do not attach OMIM:204200 to this entry — that is MONDO:0008767.

Contrast — MONDO:0008767 (do not conflate): label "neuronal ceroid lipofuscinosis 3"; definition "A condition associated with mutation(s) in the CLN3 gene, encoding battenin…"; xrefs OMIM:204200, Orphanet:228346, MEDGEN:155549, NCIT:C61258, UMLS:C0751383, DOID:0110731, GARD:0005897, NORD:843; material basis in germline mutation in CLN3 (HGNC:2074).

1.3 MONDO hierarchy and children (retrieved live)

Parents of MONDO:0019262: - MONDO:0016295 — neuronal ceroid lipofuscinosis - MONDO:0020143 — cerebral lipidosis with dementia

Direct children returned by OLS4 (/children and /descendants both returned the same four):

Child CURIE Label Gene Note
MONDO:0979341 juvenile neuronal ceroid lipofuscinosis 1 PPT1/CLN1 syn. "juvenile CLN1 disease"; xref Orphanet:699739
MONDO:0979345 juvenile neuronal ceroid lipofuscinosis 2 TPP1/CLN2 syn. "juvenile CLN2 disease"; xref Orphanet:699769
MONDO:0012188 neuronal ceroid lipofuscinosis 9 (none — withdrawn) see §4.6
MONDO:0017809 parkinsonism due to ATP13A2 deficiency ATP13A2/CLN12 Kufor-Rakeb syndrome

Plus, confirmed by direct class lookup (it is dual-parented and was missed by the descendants call):

| MONDO:0979346 | juvenile neuronal ceroid lipofuscinosis 3 | CLN3 | syn. "juvenile CLN3 disease"; xrefs Orphanet:699780, MEDGEN:1897244, UMLS:C6012317. Parents: MONDO:0019262 and MONDO:0008767. |

Two curation-relevant ontology observations:

  1. MONDO:0979346 is the correct bridging term between the onset grouping and CLN3. It sits under both MONDO:0019262 and MONDO:0008767. This is exactly the right modelling: "juvenile CLN3 disease" is simultaneously a juvenile NCL and a form of CLN3 disease. If a KB entry needs to reference "the CLN3 member of the juvenile grouping", MONDO:0979346 — not MONDO:0008767 — is the term.
  2. The grouping is under-populated relative to the literature. Orphanet has minted a juvenile CLNx disease series (ORPHA:699739 = juvenile CLN1, ORPHA:699769 = juvenile CLN2, ORPHA:699780 = juvenile CLN3), and MONDO has imported three of them. But juvenile-onset presentations are well documented for CLN5, CLN6, CLN7/MFSD8, CLN8, and CLN10/CTSD (§4), and no corresponding MONDO children exist. MONDO:0019262's asserted extension is therefore substantially narrower than its textual definition. This is a genuine ontology gap worth reporting upstream, and it means a KB entry for this grouping should enumerate members from the literature rather than from the MONDO child list.

1.4 Synonyms

Safe (onset-neutral): juvenile NCL; JNCL; juvenile neuronal ceroid lipofuscinosis; juvenile-onset neuronal ceroid lipofuscinosis; juvenile Batten disease (with caution).

Hazardous — carried by MONDO but in practice CLN3-specific in the literature: "Batten disease"; "Spielmeyer-Vogt disease"; "Spielmeyer-Sjögren disease"; "Vogt-Spielmeyer disease"; "Batten-Spielmeyer-Vogt disease". Note that "Vogt Spielmeyer disease" and "Spielmeyer Sjogren disease" are also synonyms on MONDO:0008767 — the synonym sets overlap, which is the mechanical root of the conflation.

1.5 Data provenance

Information in this report is aggregated disease-level (ontologies, OMIM/Orphanet, GeneReviews, cohort studies, case series), not individual-patient/EHR-derived. There is no EHR-scale phenotyping resource for this grouping; the DEM-CHILD and NCL Resource (UCL) patient/mutation databases are the closest thing to patient-level aggregation, and the Rochester UBDRS natural-history cohort is patient-level but CLN3-restricted.

2. Etiology

2.1 Causal factors

Monogenic, overwhelmingly autosomal recessive, biallelic loss-of-function or hypomorphic variants in a lysosomal/endolysosomal gene. There is no infectious, toxic, or environmental etiology. The one non-recessive member of the wider NCL family, autosomal-dominant DNAJC5/CLN4, is adult-onset and is not a member of this grouping (§4.7).

The unifying etiological statement for the grouping is a quantitative one rather than a gene-level one: juvenile onset arises when residual function of an NCL gene product is reduced enough to cause progressive storage, but not so severely as to produce infantile or late-infantile presentation. This "residual-activity gradient" model is the single most important mechanistic concept for MONDO:0019262 and is supported directly for CLN2:

"loss of function variants abolishing TPP1 enzyme activity lead to CLN2 disease, whereas variants that diminish TPP1 enzyme activity lead to SCAR7." — Sun Y et al., Hum Mutat 2013;34(5):706-13 (PMID:23418007)

and is the framing of the comprehensive mutation-spectrum review:

"Different mutations within the NCL spectrum can cause variable disease severity. The NCLs exemplify both phenotypic convergence or mimicry and phenotypic divergence. For example, mutations in CLN5, CLN6, MFSD8, or CLN8 can underlie the clinically similar late infantile variant NCL disease. Phenotypic divergence is exemplified by different CLN8 mutations giving rise to two very different diseases, the mild CLN8 disease, EPMR (progressive epilepsy with mental retardation), and the more severe CLN8 disease, late infantile variant." — Kousi M, Lehesjoki A-E, Mole SE. Hum Mutat 2012;33(1):42-63 (PMID:21990111)

Practical corollary for curation: the causal chain for this grouping should be modelled as [gene-specific hypomorphic lesion] → [partial residual protein function] → [slower storage accumulation] → [juvenile-window onset], with the gene as a substitutable slot — this is structurally analogous to a lysosomal_substrate_accumulation module conformer with the severity/timing dimension made explicit.

2.2 Genetic risk factors

  • Causal variants: biallelic in PPT1, TPP1, CLN3, CLN5, CLN6, MFSD8, CLN8, CTSD, ATP13A2 (see §4 for the defensibility grading).
  • Consanguinity is a major risk factor for all recessive members and is documented in most non-CLN3 juvenile reports (Cypriot CLN6 families, Chinese CLN6 family, Somali CTSD sibship, Turkish/Roma CLN7 cohorts).
  • Founder effects are strong and population-specific (§9.3): the CLN3 1.02-kb deletion in Northern Europeans; CLN5 p.Tyr392 in Finns; CLN8 p.Arg24Gly in Finns (EPMR); MFSD8 p.Thr294Lys in Roma of the former Czechoslovakia; PPT1* p.Arg122Trp in Finns.
  • No established common-variant susceptibility loci. There is no GWAS signal for NCL — this is a Mendelian entity and GWAS Catalog/PheGenI are not informative sources here.

2.3 Modifier genes

Formally identified genetic modifiers are not established for the juvenile NCLs. There is, however, strong indirect evidence of modification:

  • Intrafamilial variability with an identical genotype is documented. In a consanguineous Chinese CLN6 family, "Both patients exhibited seizures and progressive psychomotor decline and mental deterioration without visual impairment. They had different ages of onset, although they carried the same missense mutation. The affected female showed a pronounced abnormal MRI signal in the bilateral hippocampus, while her younger brother only showed a very slight abnormal signal." (Neurodegener Dis 2021;21(5-6):126-131; PMID:35609511)
  • Cross-CLN protein interdependence is a plausible modifier mechanism: "Loss of CLN3 has been shown to affect PPT1, TPP1, CLN5, and CTSD" (Zhang Y et al., CNS Neurosci Ther 2025;31(2):e70261; PMID:39925015). A hypomorphic allele in a second NCL gene could therefore plausibly modify severity — hypothesis, not established finding.

2.4 Protective factors

None identified. There are no reported protective alleles, dietary factors, or lifestyle exposures that modify onset or course. Claims to the contrary should be treated as unsupported. The only "protective" genetic phenomenon is intra-locus: a hypomorphic allele in trans to a null allele is protective relative to two nulls, shifting the phenotype from late-infantile toward juvenile/protracted. This is the mirror image of the residual-activity gradient in §2.1 and is best modelled as allelic severity, not as a protective factor.

2.5 Gene–environment interactions

Not applicable / none documented. No GxE interaction has been demonstrated for any NCL. Intercurrent febrile illness can lower seizure threshold and precipitate clinical deterioration, but this is a nonspecific epilepsy phenomenon and not a disease-modifying interaction.

3. Phenotypes

⚠️ Frequency caveat, stated once and applying throughout this section. Quantitative frequency data for "juvenile NCL" in the literature are overwhelmingly derived from CLN3 cohorts (the Rochester UBDRS cohort, the DEM-CHILD/NCL Resource registries, Scandinavian and Danish series). Applying those frequencies to the grouping over-weights CLN3 and imports precisely the conflation this entry exists to avoid. Where I give a frequency below, I state which population it came from. For a dismech entry, the defensible position is to curate the grouping's phenotypes with frequency: omitted for most terms, per the frequency-evidence SOP, and to attach quantitative frequencies only at the member (juvenile CLN3 disease, MONDO:0979346) level.

3.1 Ophthalmological (the cardinal presenting domain)

Phenotype HPO term Onset Course Notes
Progressive visual loss HP:0000529 Progressive visual loss 4–7 y (CLN3); 6–11 y (CLN6, CLN7) Progressive Herald symptom in most members; absent in CLN8/EPMR and in some CLN6
Rod-cone dystrophy HP:0000510 Rod-cone dystrophy juvenile Progressive
Retinal dystrophy HP:0000556 Retinal dystrophy juvenile Progressive
Bull's eye maculopathy HP:0011504 Bull's eye maculopathy juvenile Progressive Classic in CLN3; drives Stargardt misdiagnosis
Pigmentary retinopathy HP:0000580 Pigmentary retinopathy juvenile Progressive
Macular degeneration HP:0000608 Macular degeneration juvenile Progressive Isolated in non-syndromic MFSD8 maculopathy
Optic atrophy HP:0000648 Optic atrophy juvenile Progressive "disc pallor 56%" in a mixed pediatric NCL cohort (PMID:39281238)
Attenuation of retinal blood vessels HP:0007843 juvenile Progressive
Abnormal electroretinogram HP:0000512 Abnormal electroretinogram early, often pre-symptomatic → extinguished ERG becomes HP:0000550 Undetectable electroretinogram
Abnormal fundus autofluorescence imaging HP:0030602 juvenile
Blindness HP:0000618 Blindness typically within 2–4 y of visual onset

Quality-of-life impact: vision loss in this window is uniquely destructive because it lands at the start of formal literacy acquisition. It forces immediate transition to braille/assistive technology — which is then itself lost as dementia advances, producing a documented "double loss" and a well-described family-reported crisis point. Loss of independent mobility and reading are the two dominant QoL domains in the CLN3 literature.

3.2 Cognitive / behavioural / psychiatric

Phenotype HPO term Notes
Cognitive impairment HP:0100543 Cognitive impairment
Dementia HP:0000726 Dementia Progressive, onset ~1–3 y after visual failure
Developmental regression HP:0002376 Developmental regression
Intellectual disability HP:0001249 Intellectual disability Progresses to HP:0010864 Severe / HP:0002187 Profound
Loss of speech HP:0002371 Loss of speech
Psychosis HP:0000709 Psychosis Prominent in adolescent CLN3; can precede or dominate
Hallucinations HP:0000738 Hallucinations; HP:0002367 Visual hallucination
Anxiety HP:0000739 Anxiety
Aggressive behavior HP:0000718 Aggressive behavior
Attention deficit hyperactivity disorder HP:0007018 Early, often pre-diagnostic
Sleep disturbance HP:0002360 Sleep disturbance High family-burden item

The psychiatric phenotype is a genuine differentiator within the grouping: florid psychosis with hallucinations in an adolescent with visual failure is characteristically CLN3, whereas the CLN6 and CLN8 juvenile forms are dominated by seizures and motor decline with less prominent psychosis.

3.3 Seizures / epilepsy

Phenotype HPO term Notes
Seizure HP:0001250 Seizure
Bilateral tonic-clonic seizure HP:0002069 Most common type
Generalized myoclonic seizure HP:0002123
Myoclonus HP:0001336 Myoclonus Often action/stimulus-sensitive
Photosensitive myoclonic seizure HP:0001327
Generalized non-motor (absence) seizure HP:0002121
Status epilepticus HP:0002133 Later stages

Seizure onset is the defining first symptom in the CLN8/EPMR member — Ranta et al. describe EPMR as "an autosomal recessive disorder characterized by onset of generalized seizures between 5 and 10 years, and subsequent progressive mental retardation" (Nat Genet 1999;23(2):233-6; PMID:10508524). That onset window is squarely juvenile, but the phenotype lacks retinopathy — which is why a purely vision-anchored definition of "juvenile NCL" would wrongly exclude it.

In a mixed pediatric NCL cohort (median onset 5.46 ± 1.95 y), "myoclonic seizures in 68%, and motor difficulty in 24%" were the presenting symptoms, with "visual impairment (80%), global developmental delay (56%), and disc pallor (56%)" as primary features (Pak J Med Sci 2024;40(8):1638-1643; PMID:39281238). Note this cohort was CLN6-dominant (42%), not CLN3-dominant, which explains the seizure-first skew relative to classic CLN3 descriptions.

3.4 Motor: extrapyramidal, cerebellar, pyramidal

Phenotype HPO term Notes
Ataxia / Progressive cerebellar ataxia HP:0001251 / HP:0002073 Cardinal in CLN5, CLN6, CLN10, and TPP1-SCAR7
Gait ataxia HP:0002066 Gait ataxia
Dysarthria HP:0001260 Dysarthria
Parkinsonism HP:0001300 Parkinsonism Prominent in CLN3 adolescence and definitional in ATP13A2/CLN12
Bradykinesia HP:0002067; Rigidity HP:0002063
Dystonia HP:0001332 Dystonia
Spasticity HP:0001257 Spasticity Prominent in the Cypriot CLN6 juvenile families
Abnormal pyramidal sign HP:0007256
Loss of ambulation HP:0002505 Loss of ambulation Second decade
Tremor HP:0001337 Tremor

3.5 Other systemic

Phenotype HPO term Notes
Dysphagia HP:0002015 Dysphagia Drives gastrostomy decision; aspiration is a major mortality route
Scoliosis HP:0002650 Scoliosis Secondary to immobility
Peripheral neuropathy HP:0009830 Peripheral neuropathy Documented in CTSD/CLN10 juvenile ("sensory axonal neuropathy", PMID:25298308)
Cardiac involvement HP:0011675 Arrhythmia (⚠️ ID not re-verified against the local cache) Ventricular hypertrophy, repolarisation abnormalities, and sinus-node dysfunction are described in CLN3 adolescents/adults; not established for other members

3.6 Neuroimaging and laboratory

Finding HPO term Notes
Cerebral atrophy HP:0002059 Cerebral atrophy
Cerebellar atrophy HP:0001272 Cerebellar atrophy Prominent in CLN5, CLN6, CLN7
Generalized cerebral atrophy/hypoplasia HP:0007058
Neuronal loss in central nervous system HP:0002529 Neuropathological
Gliosis HP:0002171 Gliosis Neuropathological; reactive astro-/microgliosis
Vacuolated lymphocytes HP:0001922 (⚠️ ID not present in the local HP cache and not verified this session — verify before use) CLN3-specific; a genuinely discriminating bedside test within the grouping

3.7 Phenotype characteristics summary

  • Onset: juvenile, ~5–10 y (grouping-defining). Range across defensible members: ~4 y (some CLN6/CLN5) to ~15 y (CTSD family A; some CLN7 protracted).
  • Severity: severe and uniformly fatal in the classic members; variable across the grouping — protracted CLN2, CLN5, and CLN7 forms can survive into the fourth decade.
  • Progression: progressive, monotonic, without remission. Not episodic or relapsing.
  • Frequency: see the caveat opening §3.

4. Genetic / Molecular Information — the gene-by-gene core of this report

This is the section the entity requires. Below, each NCL gene is graded for whether a juvenile-onset presentation is defensibly attributable to it.

4.0 Grading key

  • Tier A — Established. Multiple independent reports, or an authoritative classification source (GeneReviews Table 1 / Kousi 2012 / Mole & Cotman 2015) lists juvenile onset as a recognised phenotype for the gene.
  • Tier B — Reported, limited. Juvenile onset reported in one or few families; real but thinly evidenced.
  • Tier C — Not defensible as juvenile. The gene's recognised onset windows are infantile, late-infantile, or adult. Do not list as a member.
  • Tier X — Withdrawn / invalid.

The two anchor classification sources agree substantially. GeneReviews Neuronal Ceroid-Lipofuscinoses (NBK1428) Table 1, retrieved this session:

CLN Gene OMIM Classic phenotype Atypical phenotypes
CLN1 PPT1 256730 Infantile Late infantile, Juvenile, Adult
CLN2 TPP1 204500 Late infantile Congenital/infantile, Juvenile, Late juvenile/protracted, Adult
CLN3 CLN3 204200 Juvenile Protracted, Isolated retinal degeneration
CLN4 DNAJC5 162350 Adult —
CLN5 CLN5 256731 Late infantile Congenital, Infantile, Juvenile, Protracted, Teenage, Adult
CLN6 CLN6 601780, 204300 Late infantile to juvenile Protracted, Teenage, Adult Kufs A & B
CLN7 MFSD8 610951 Late infantile Juvenile / late juvenile
CLN8 CLN8 600143, 610003 Late infantile to juvenile —
CLN10 CTSD 610127 Congenital Late infantile, Juvenile, Adult
CLN11 GRN 614706 Teenage to adult —
CLN13 CTSF 615362 Adult Kufs type B —
CLN14 KCTD7 611726 Late infantile —

Mole & Cotman 2015 (Biochim Biophys Acta 1852(10 Pt B):2237-41; PMID:26026925) Table 2 concurs and additionally lists CLN12/ATP13A2 → juvenile.

4.1 Tier A — CLN3 (HGNC:2074) — the modal, but not the definitional, member

  • MONDO: disease MONDO:0008767; juvenile member term MONDO:0979346. OMIM: 204200. Protein: CLN3/battenin, a polytopic lysosomal/endosomal membrane protein of incompletely defined function.
  • Onset: 4–7 y with visual failure. Course: vision → cognition/behaviour → seizures (~8–13 y) → extrapyramidal motor decline → death typically in the third decade.
  • Variant spectrum: dominated by a single founder allele, a ~1.02-kb genomic deletion removing exons 7 and 8 (c.461-280_677+382del966, historically "1 kb deletion"), reported in roughly 80–85% of disease alleles in Northern European ancestry, with ~70–75% of patients homozygous. ⚠️ These specific percentages are from the standard literature (International Batten Disease Consortium, Cell 1995) but were not re-verified against a fetched abstract in this session — verify before curating as evidence. Remaining alleles are missense, nonsense, frameshift, and splice.
  • Functional consequence: loss of function. The common deletion produces a frameshifted truncated product.
  • Allelic non-NCL phenotype: isolated/non-syndromic retinal degeneration from hypomorphic CLN3 genotypes — clinically important because such patients are juvenile-onset and present to retina clinics.
  • Ultrastructure: fingerprint profiles, with curvilinear and rectilinear components (GeneReviews Table 2).
  • Discriminating lab feature: vacuolated peripheral lymphocytes, essentially unique to CLN3 within the grouping.
  • Carrier frequency: ~1/500 in the US when adjusted for ethnic diversity (Gene 2016; see §4.14).

4.2 Tier A — PPT1 / CLN1 (HGNC:9325) — juvenile CLN1 disease

  • MONDO: MONDO:0979341 ("juvenile neuronal ceroid lipofuscinosis 1"; Orphanet:699739); gene-level MONDO:0009744. OMIM: 256730. Protein: palmitoyl-protein thioesterase 1, a soluble lysosomal enzyme removing thioester-linked palmitate from S-acylated proteins.
  • Defensibility: strong and long-established. The defining paper is explicitly titled for this phenotype: "Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits" (Mitchison HM et al., Hum Mol Genet 1998;7(2):291-7; PMID:9425237). It reported: "Five mutations in the PPT gene were identified: three missense mutations, Thr75Pro, Asp79Gly, Leu219Gln, and two nonsense mutations, Leu10STOP and Arg151STOP."
  • The diagnostic trap this paper solved: juvenile CLN1 combines a juvenile clinical course with infantile-type ultrastructure (GROD, granular osmiophilic deposits). A pathologist who reads GROD and reports "infantile NCL" will contradict the clinician. Mitchison et al. concluded this demonstrates "the correlation which exists between genetic basis and ultrastructural changes in the NCLs" — i.e. ultrastructure tracks the gene, not the onset age. This is the single most useful ultrastructural rule for triaging a juvenile NCL: GROD in a juvenile patient means PPT1 or CTSD, not CLN3.
  • Genotype–phenotype: juvenile onset associates with missense/hypomorphic alleles retaining partial PPT1 activity; null/null gives classic infantile CLN1 (Santavuori-Haltia).
  • Biochemically confirmable: PPT1 enzyme assay in leukocytes/fibroblasts/dried blood spot. This makes juvenile CLN1 one of only three members with a cheap, definitive, non-sequencing first-line test.
  • Carrier frequency: highest of any NCL gene — 1/75 in Finns; ~1/500 US-adjusted (Gene 2016).

4.3 Tier A — TPP1 / CLN2 (HGNC:2073) — juvenile and late-juvenile/protracted CLN2

  • MONDO: MONDO:0979345 ("juvenile neuronal ceroid lipofuscinosis 2"; Orphanet:699769); gene-level MONDO:0009746. OMIM: 204500. Protein: tripeptidyl peptidase 1, a soluble lysosomal serine protease.
  • Defensibility: strong. GeneReviews lists both "Juvenile" and "Late juvenile/protracted" as recognised atypical CLN2 phenotypes. The historically important report is Wisniewski KE et al., "Reevaluation of neuronal ceroid lipofuscinoses: atypical juvenile onset may be the result of CLN2 mutations" (Mol Genet Metab 1999) — ⚠️ the exact-title PubMed query failed this session and I could not confirm its PMID; verify before citing.
  • The best-characterised juvenile TPP1 phenotype is SCAR7. Sun et al. showed that autosomal recessive spinocerebellar ataxia 7 is allelic to CLN2: SCAR7 patients "showed ataxia and low activity of tripeptidyl-peptidase 1, but no ophthalmologic abnormalities or epilepsy", and proposed that "loss of function variants abolishing TPP1 enzyme activity lead to CLN2 disease, whereas variants that diminish TPP1 enzyme activity lead to SCAR7." (Hum Mutat 2013;34(5):706-13; PMID:23418007). SCAR7 = MONDO:0012452 / OMIM:609270.
  • Why this matters for MONDO:0019262: the TPP1 juvenile/protracted phenotype is a cerebellar-ataxia-first presentation without the retinopathy that anchors the classic juvenile gestalt. A juvenile NCL grouping defined only by "vision loss + seizures + dementia" will miss it.
  • Biochemically confirmable: TPP1 enzyme assay (leukocyte / dried blood spot). This is the highest-yield single test in the entire grouping, because CLN2 is the only NCL with an approved disease-modifying therapy (§12.1).
  • Ultrastructure: curvilinear profiles.
  • Carrier frequency: ~1/500 US-adjusted (Gene 2016).

4.4 Tier A — CLN5 (HGNC:2076) — juvenile is the predominant onset outside Finland

  • MONDO: MONDO:0008768 (gene-level) — no juvenile-specific MONDO child exists. OMIM: 256731. Protein: CLN5, a soluble lysosomal glycoprotein; recently characterised as a lysosomal bis(monoacylglycero)phosphate synthase.
  • Defensibility: strong, and the evidence is directionally surprising. CLN5 is classically the "Finnish variant late-infantile" gene (vLINCLFin, onset 4.5–6 y — already at the late-infantile/juvenile boundary). But in non-Finnish populations juvenile onset predominates. Xin W et al. screened 47 clinically diagnosed, molecularly unsolved NCL patients and found 10 with pathogenic CLN5 variants (11 previously undescribed), concluding: "The age at disease onset in this cohort is predominantly juvenile rather than late infantile. Importantly, we have identified 2 adult-onset patients who share a common pathogenic allele." (Neurology 2010;74(7):565-71; PMID:20157158). The title itself is the claim: "CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL."
  • Clinical texture: the same paper notes most patients presented with motor and visual impairment rather than seizures.
  • Founder allele: the Finnish major mutation p.Tyr392* (historically "2467A>T").
  • Ultrastructure: rectilinear, curvilinear, fingerprint.
  • Curation note: CLN5 is arguably the strongest single argument that MONDO:0019262 must not be modelled as CLN3 — a non-Finnish patient with a juvenile NCL and no CLN3 variant has CLN5 as a leading candidate.

4.5 Tier A — CLN6 (HGNC:2077) — juvenile onset is in the classic, not atypical, range

  • MONDO: MONDO:0011503 (gene-level) — no juvenile-specific child. OMIM: 601780 (CLN6), 204300 (Kufs type A). Protein: CLN6, a non-glycosylated ER transmembrane protein implicated in lysosomal acidification and in the CLN6–CLN8 (EGRESS) complex trafficking lysosomal enzymes from ER to Golgi.
  • Defensibility: strong. GeneReviews classifies the classic phenotype as "Late infantile to juvenile" — CLN6 straddles the boundary by default. Mole & Cotman list "juvenile cerebellar ataxia" and "teenage progressive myoclonic epilepsy" among CLN6 phenotypes.
  • Two recent, well-characterised juvenile-onset families, both with a phenotype that breaks the vision-first rule:

Kyriakou K et al. reported two Greek-Cypriot families: "We report clinical and genetic findings of three patients from two Greek-Cypriot families (families 915 and 926) with JNCL. All patients were males, and the first symptoms appeared at the age of 6 years. The proband of family 926 presented with loss of motor abilities, ataxia, spasticity, seizure, and epilepsy. The proband of family 915 had ataxia, spasticity, dysarthria, dystonia, and intellectual disability. Both probands did not show initial signs of vision and/or hearing loss." Molecular findings: "family 926 revealed two CLN6 biallelic variants: the novel, de novo p.Tyr295Cys and the known p.Arg136His variants. In family 915, both patients were homozygous for the p.Arg136His CLN6 variant." — Front Genet 2021;12:746101 (PMID:34868216), titled "A Novel CLN6 Variant Associated With Juvenile Neuronal Ceroid Lipofuscinosis in Patients With Absence of Visual Loss as a Presenting Feature."

A consanguineous Chinese family with a novel homozygous CLN6 c.14G>T (p.Arg5Leu): "Both patients exhibited seizures and progressive psychomotor decline and mental deterioration without visual impairment." — Neurodegener Dis 2021;21(5-6):126-131 (PMID:35609511), titled "Juvenile-Onset Kufs Disease in a Chinese Consanguineous Family due to CLN6 Mutation."

  • The absent-visual-loss signature is the key CLN6 discriminator within the juvenile grouping and should be curated explicitly. Together with CLN8/EPMR, it establishes that visual failure is typical of MONDO:0019262 but not necessary.
  • Also note: CLN6 additionally causes adult Kufs type A (autosomal recessive progressive myoclonic epilepsy) — so one gene spans late-infantile, juvenile, teenage, and adult windows. CLN6 is the clearest example of why gene ≠ onset class.
  • Epidemiological weight: CLN6 was the most common genotype (42%) in a 153-patient pediatric NCL cohort (PMID:39281238), well ahead of CLN2 (16%) and CLN7 (12%).

4.6 Tier A — MFSD8 / CLN7 (HGNC:28486) — juvenile / late-juvenile protracted

  • MONDO: MONDO:0012588 (gene-level) — no juvenile-specific child. OMIM: 610951. Protein: MFSD8/CLN7, a lysosomal major-facilitator-superfamily transmembrane transporter.
  • Defensibility: strong. GeneReviews lists "Juvenile/late juvenile" as the recognised atypical phenotype. Kousi et al.'s foundational MFSD8 paper, while framed around variant late-infantile disease — "With one exception, the CLN7/MFSD8 mutation positive patients present a phenotype indistinguishable from the other vLINCL forms" (Brain 2009;132(Pt 3):810-9; PMID:19201763) — describes that exception as a Dutch patient with a protracted course who presented at age 11 with visual failure, with motor impairment and seizures in his mid-twenties and mental/speech regression in his thirties. That is a juvenile-onset, decades-long MFSD8 NCL.
  • Founder allele: p.Thr294Lys, homozygous in 14 Roma patients from 12 families of the former Czechoslovakia.
  • Allelic non-syndromic juvenile eye disease: Roosing S et al. identified compound-heterozygous MFSD8 variants causing nonsyndromic autosomal recessive macular dystrophy with central cone involvement, normal/subnormal full-field ERG but reduced multifocal ERG. Both families carried the mild missense p.Glu336Gln in trans to a severe allele (protein-truncating in one family, splicing-defect in the other), supporting an explicit dose model: "proposing a genotype-phenotype model where variant combinations determine disease severity." (Ophthalmology 2015;122(1):170-9; PMID:25227500).
  • Why this matters here: MFSD8 produces a graded juvenile-onset visual spectrum from isolated maculopathy (no neurodegeneration) through juvenile NCL — the residual-activity gradient of §2.1 made visible in one gene.
  • Ultrastructure: rectilinear, fingerprint.

4.7 Tier A — CLN8 (HGNC:2079) — EPMR / Northern epilepsy: juvenile by age, atypical by phenotype

  • MONDO: MONDO:0009746-adjacent; gene-level MONDO:0008776 (Northern epilepsy) / MONDO:0012531 (CLN8 vLINCL) — ⚠️ these two CURIEs were not individually verified this session. OMIM: 600143 (EPMR/Northern epilepsy), 610003 (CLN8 vLINCL). Protein: CLN8, an ER/ERGIC transmembrane protein; partner of CLN6 in the EGRESS complex.
  • Defensibility: strong on age, with an explicit clinical caveat. GeneReviews classifies the classic CLN8 phenotype as "Late infantile to juvenile." Ranta et al.'s positional cloning paper defines EPMR as "an autosomal recessive disorder characterized by onset of generalized seizures between 5 and 10 years, and subsequent progressive mental retardation", caused by a homozygous missense mutation "(70C-->G, R24G) that was not found in homozygosity in 433 controls" (Nat Genet 1999;23(2):233-6; PMID:10508524).
  • 5–10 years is the textbook juvenile window. EPMR therefore belongs in MONDO:0019262 on the grouping's own onset criterion — but it presents with epilepsy, not vision loss, and is comparatively mild (patients survive into middle age with intellectual disability).
  • CLN8 is also the canonical illustration of intra-genic phenotypic divergence. Kousi et al.: "Phenotypic divergence is exemplified by different CLN8 mutations giving rise to two very different diseases, the mild CLN8 disease, EPMR (progressive epilepsy with mental retardation), and the more severe CLN8 disease, late infantile variant." (PMID:21990111)
  • Founder allele: p.Arg24Gly, essentially restricted to a region of northern Finland (Kainuu), hence "Northern epilepsy". The Turkish vLINCL CLN8 alleles are distinct and produce the more severe late-infantile disease.
  • Ultrastructure: curvilinear-like fingerprint, granular.

4.8 Tier B — CTSD / CLN10 (HGNC:2529) — juvenile-onset ataxia with retinopathy

  • MONDO: MONDO:0012350 (gene-level) — ⚠️ CURIE not verified this session. OMIM: 610127. Protein: cathepsin D, a soluble lysosomal aspartyl protease.
  • Defensibility: reported and credible, but few families. GeneReviews lists "Juvenile" among CTSD atypical phenotypes (classic = congenital). The primary evidence:
  • Steinfeld R et al., "Cathepsin D deficiency is associated with a human neurodegenerative disorder" (Am J Hum Genet 2006; PMID:16685649) — established CTSD as an NCL gene, including a juvenile-onset sibship.
  • Two consanguineous pedigrees "both with a juvenile onset of NCL" were characterised in Neurology 2014;83(20):1873-5 (PMID:25298308), titled "Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology." Family A carried a "homozygous missense mutation (p.G149V in exon 4 of CTSD)" with "juvenile onset of cerebellar ataxia and retinitis pigmentosa at around 15 years, which progressed to significant motor impairment and cognitive decline." Family B carried a "homozygous missense mutation… (p.Arg399His in exon 9 of CTSD)" with an "earlier age at onset of 8 years" and additionally "sensory axonal neuropathy." Fibroblast assay showed "a significant reduction in enzyme activity compared to controls." Muscle biopsy showed "granulovacuolar material in angular atrophic fibers in addition to the granular osmiophilic deposits that are diagnostic for neuronal ceroid lipofuscinosis."
  • Notably, in a 153-patient pediatric NCL cohort, CLN10 was the only genotype presenting exclusively as juvenile (PMID:39281238) — a small-n but striking observation.
  • Biochemically confirmable: cathepsin D enzyme activity assay in fibroblasts. Third of the three assayable members.
  • Ultrastructure: GROD — the other GROD-in-a-juvenile gene alongside PPT1.

4.9 Tier B — ATP13A2 / CLN12 (HGNC:30213) — juvenile NCL / Kufor-Rakeb syndrome

  • MONDO: MONDO:0017809 ("parkinsonism due to ATP13A2 deficiency") — this is an asserted direct child of MONDO:0019262. OMIM: 606693. Protein: ATP13A2/PARK9, a lysosomal P5B-type polyamine transporting ATPase.
  • Defensibility: reported, single-family origin for the NCL designation, but ontologically endorsed. Bras J et al. described a family with typical NCL pathology in which exome sequencing found a homozygous ATP13A2 mutation segregating with disease, noting that "Mutations in ATP13A2 are a known cause of Kufor-Rakeb syndrome (KRS), a rare parkinsonian phenotype with juvenile onset", and concluding that NCL and KRS may share etiological mechanisms and "implicate the lysosomal pathway in Parkinson's disease." (Hum Mol Genet 2012;21(12):2646-50; PMID:22388936). Mole & Cotman Table 2 lists CLN12/ATP13A2 as juvenile. Zhang et al. 2025 give onset ~13 y.
  • Phenotype: juvenile-onset parkinsonism with pyramidal signs, supranuclear gaze palsy, and cognitive decline (Kufor-Rakeb), plus NCL storage. The extrapyramidal dominance distinguishes it, though note that CLN3 adolescents also develop parkinsonism.
  • Caveat for curation: the NCL designation for ATP13A2 rests on a small evidence base and the gene is far better known as a parkinsonism gene. Model as a member with explicit acknowledgement of the thin evidence, and preserve the KRS identity rather than flattening it into "juvenile NCL".

4.10 Tier B/borderline — GRN / CLN11 (HGNC:4601) — adolescent-to-young-adult, mostly outside the juvenile window

  • MONDO: MONDO:0013839 (⚠️ not verified this session). OMIM: 614706. Protein: progranulin, a secreted glycoprotein processed to granulin peptides; lysosomal chaperone functions including interaction with prosaposin and cathepsin D.
  • Defensibility: weak as a juvenile member; strong as an adult/teenage member. GeneReviews classifies CLN11 as "Teenage to adult." The defining paper reported two siblings homozygous for c.813_816del (p.Thr272Serfs*10), and its central point is the dosage dichotomy: "Heterozygous mutations in GRN are a major cause of frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP)… The age-at-onset and neuropathology of FTLD-TDP and NCL are markedly different. Our findings reveal an unanticipated link between a rare and a common neurological disorder and illustrate pleiotropic effects of a mutation in the heterozygous or homozygous states." (Smith KR et al., Am J Hum Genet 2012;90(6):1102-7; PMID:22608501). Reexamination of progranulin-deficient mice "revealed rectilinear profiles typical of NCL."
  • Onset in homozygous GRN NCL is typically ~20–25 y (retinal dystrophy first, then ataxia, seizures, cognitive decline). Zhang et al. 2025 quote a wider "5–25 years" band; I could not verify a specific well-documented childhood-onset homozygous GRN case in this session.
  • Recommendation: do NOT list GRN/CLN11 as a core member of MONDO:0019262. List it as an adjacent, adult-boundary entity to be excluded in differential reasoning, with a note that the youngest reported onsets brush the upper edge of adolescence.

4.11 Tier C — DNAJC5 / CLN4 (HGNC:24586) — adult only; exclude

  • OMIM: 162350. Protein: cysteine-string protein alpha (CSPα), a synaptic-vesicle co-chaperone.
  • Autosomal DOMINANT adult-onset Kufs disease, onset typically mid-20s to 40s, with progressive myoclonic epilepsy and dementia. GeneReviews: classic phenotype "Adult"; no atypical phenotypes listed.
  • Explicitly not juvenile. The current gene list for adult NCL is stated cleanly in Jedličková I et al.: "Adult-onset neuronal ceroid lipofuscinoses (ANCL, Kufs disease) are rare hereditary neuropsychiatric disorders characterized by intralysosomal accumulation of ceroid in tissues… Although several causative genes have been identified (DNAJC5, CLN6, CTSF, GRN, CLN1, CLN5, ATP13A2), the genetic underpinnings of ANCL in some families remain unknown." (Eur J Hum Genet 2020;28(6):783-789; PMID:31919451). That paper also carries a diagnostic caution worth recording: a 30-bp in-frame DNAJC5 duplication "was not detected initially by standard Sanger sequencing due to a preferential PCR amplification of the shorter wild-type allele and allelic dropout of the mutated DNAJC5 allele. It was also missed by subsequent whole-exome sequencing (WES)."
  • Note the overlap this creates: CLN6, CTSF, GRN, CLN1, CLN5, ATP13A2 appear in both the adult list above and (for CLN1, CLN5, CLN6, ATP13A2) the juvenile list. The same gene can be a member of the juvenile grouping and of the adult grouping via different alleles. This is the central structural fact about onset-defined NCL groupings and must not be modelled as an inconsistency.

4.12 Tier C — CTSF / CLN13 (HGNC:2531) — adult Kufs type B; exclude

  • OMIM: 615362. Protein: cathepsin F, a lysosomal cysteine protease. GeneReviews: "Adult Kufs type B", no atypical phenotypes. Onset typically after age 20 (Zhang 2025: "After 20 years"). Ultrastructure: GROD and fingerprint.

4.13 Tier C — KCTD7 / CLN14 (HGNC:21957) — infantile/late-infantile PME; exclude

  • OMIM: 611726 (progressive myoclonic epilepsy 3 with or without intracellular inclusions). Protein: potassium channel tetramerisation domain-containing 7, a cytoplasmic/peripherally membrane-associated protein. GeneReviews: classic "Late infantile"; Zhang 2025 gives onset ~14 months. No credible juvenile-onset NCL attribution.

4.14 Tier X — "CLN9" — withdrawn; the label survives in ontologies as an artefact

  • MONDO:0012188 ("neuronal ceroid lipofuscinosis 9") is an asserted direct child of MONDO:0019262 — but there is no CLN9 gene. OMIM 609055 remains as a legacy entry.
  • History: Schulz A et al. (2004; PMID:15349861, "Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant") described a juvenile-onset NCL variant in two Serbian sisters and two German brothers, attributed to a putative new gene "CLN9". Kousi et al. still listed CLN4 and CLN9 as "provisionally named" in 2012 (PMID:21990111). El Haddad et al. (2012) subsequently identified a homozygous CLN5 nonsense mutation in affected siblings from one of the Schulz families, reclassifying that family as CLN5. ⚠️ The El Haddad PMID and the exact CLN5 variant nomenclature were reported to me in secondary search summaries and were not verified against a primary abstract this session — verify before citing.
  • Curation guidance: CLN9 should be recorded as an invalid/withdrawn designation, retained only to explain legacy literature and legacy ontology terms. Do not curate it as a distinct genetic member. Its presence as a MONDO child of MONDO:0019262 is a defect worth reporting upstream, alongside the missing CLN5/CLN6/CLN7/CLN8/CLN10 juvenile children (§1.3).

4.15 Population allele frequencies and carrier burden

The best single quantitative source is an ExAC-based analysis of ~61,000 exomes across twelve NCL genes:

"Estimates of NCL incidence range from 0.6 to 14 per 100,000 live births but vary widely between populations and are influenced by whether patients are classified based upon clinical or genetic criteria. We investigated mutations in twelve NCL genes in ~61,000 individuals represented in the Exome Aggregation Consortium (ExAC) whole exome sequencing database… Carrier frequency was dependent on ethnicity, with the highest (1/75) observed for PPT1 in the Finnish. When data are adjusted for ethnic diversity within the USA, PPT1, TPP1 and CLN3 carrier frequencies were found to be the highest of the NCLs, each at ~1/500." — Gene 2016;593(2):284-91 (PMID:27553520)

That paper also carries a warning directly relevant to ClinVar-based curation:

"the analysis identified numerous variants that are annotated as pathogenic in public repositories but have a predicted frequency that is not consistent with patient studies. These variants appear to be neutral polymorphisms that are reported as pathogenic without validation."

Variant classification and origin: all variants are germline; ACMG/AMP classification applies; COSMIC/TCGA/ICGC are not applicable (no somatic component). ClinVar and the NCL Mutation and Patient Database (UCL, ucl.ac.uk/ncl-disease) are the two primary variant resources; the latter is NCL-specific and organises Patient Datasheets and Mutation Datasheets per gene. Kousi et al. catalogued 365 NCL-causing mutations across eight genes as of 2012 (PMID:21990111); Mole & Cotman put the figure at "more than a dozen genes containing over 430 mutations" by 2015 (PMID:26026925).

4.16 Epigenetics and chromosomal abnormalities

  • Epigenetics: no established disease-causing epigenetic mechanism. No imprinting, no methylation-defined subtype. ENCODE/Roadmap/DiseaseMeth are not informative for this entity.
  • Chromosomal abnormalities: the only recurrent structural variant of note is the CLN3 ~1.02-kb intragenic deletion — a small CNV detectable by targeted PCR or by exon-level dosage analysis, not by routine karyotype or standard-resolution chromosomal microarray. Larger multi-exon deletions occur in several NCL genes and are a recognised cause of "one variant found, one missing" cases. Karyotype and FISH have no role. CMA has a limited role only if it is exon-resolution over the relevant genes.

5. Environmental Information

  • Environmental factors: none. No toxin, radiation, pollutant, or occupational exposure contributes to NCL causation. CTD/TOXNET/EPA are not informative sources for this entity.
  • Lifestyle factors: none causal. Nutritional status and aspiration risk affect outcome, not etiology.
  • Infectious agents: none. NCL is not infectious, not triggered by infection, and has no zoonotic dimension. Intercurrent febrile illness may transiently worsen seizure control — a nonspecific epilepsy effect.

This section is genuinely empty for MONDO:0019262 and should be curated as such, rather than padded.

6. Mechanism / Pathophysiology

6.1 The shared final common pathway

All members converge on lysosomal dysfunction with accumulation of autofluorescent ceroid-lipofuscin, then on neuronal death with regional selectivity. The proximal defects are heterogeneous — soluble lysosomal enzymes (PPT1, TPP1, CTSD, CTSF), a soluble lysosomal protein (CLN5), a secreted protein (GRN), cytosolic/membrane-peripheral proteins (DNAJC5, KCTD7), and multiple transmembrane proteins at different subcellular locations (CLN3, CLN6, MFSD8, CLN8, ATP13A2):

"These genes encode lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), a soluble lysosomal protein (CLN5), a protein in the secretory pathway (CLN11), two cytoplasmic proteins that also peripherally associate with membranes (CLN4, CLN14), and many transmembrane proteins with different subcellular locations (CLN3, CLN6, CLN7, CLN8, CLN12). For most NCLs, the function of the causative gene has not been fully defined." — Mole & Cotman, PMID:26026925

Proposed causal chain for the grouping (upstream → downstream):

  1. [MOLECULAR] Biallelic hypomorphic variant → partial loss of gene-product function (residual activity in the juvenile-permissive range).
  2. [MOLECULAR] Failure of the specific lysosomal degradative/transport step → substrate accumulation.
  3. [CELLULAR] Progressive intralysosomal accumulation of autofluorescent ceroid-lipofuscin storage material.
  4. [CELLULAR] Autophagic-lysosomal pathway failure — accumulation of autophagic vacuoles, impaired autophagosome-lysosome fusion, impaired lysosomal acidification.
  5. [CELLULAR/TISSUE] Reactive microgliosis and astrogliosis; neuroinflammation, which in NCL models precedes and predicts regional neuron loss.
  6. [TISSUE] Selective neurodegeneration — photoreceptors and retinal ganglion cells early (accounting for the vision-first phenotype), then cortical layers II/III/V, cerebellar Purkinje and granule cells, thalamic relay nuclei.
  7. [ORGANISM] Visual failure → cognitive/behavioural decline → epilepsy → motor decline → death.

6.2 The stored material — a genuine mechanistic discriminator

The storage body composition is not uniform, and this maps onto ultrastructure and onto gene:

  • In most NCLs the major stored protein is subunit c of mitochondrial ATP synthase (SCMAS) — established by Palmer and colleagues: "Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease)", Am J Med Genet 1992 (PMID:1535179), and the companion immunocytochemical study, Am J Med Genet 1995 (PMID:7668326). This corresponds to curvilinear/rectilinear/fingerprint ultrastructure.
  • In CLN1/PPT1 and CLN10/CTSD, the predominant stored proteins are instead saposins A and D, and the ultrastructure is GROD. ⚠️ The saposin attribution is standard in the field (Tyynelä et al.) but I did not verify a specific PMID for it this session.

Curation consequence: a juvenile NCL entry should model two storage-composition branches (SCMAS-type vs saposin/GROD-type), not one.

6.3 Gene-specific proximal mechanisms

Gene Protein Proximal molecular defect Suggested GO terms
PPT1 palmitoyl-protein thioesterase 1 Failure to remove thioester-linked palmitate from S-acylated proteins in the lysosome GO:0008474 palmitoyl-(protein) hydrolase activity; GO:0006508 proteolysis
TPP1 tripeptidyl peptidase 1 Failure of N-terminal tripeptide removal from small polypeptides in the lysosome GO:0008240 tripeptidyl-peptidase activity; GO:0006508 proteolysis
CTSD cathepsin D Loss of lysosomal aspartyl endopeptidase activity GO:0004190 aspartic-type endopeptidase activity
CLN3 battenin Undefined; implicated in lysosomal pH/osmoregulation, membrane trafficking, glycerophosphodiester efflux GO:0007040 lysosome organization
CLN5 CLN5 Soluble lysosomal protein; BMP (bis(monoacylglycero)phosphate) synthase activity GO:0007040 lysosome organization
CLN6, CLN8 CLN6, CLN8 ER/ERGIC EGRESS complex — trafficking of soluble lysosomal enzymes from ER to Golgi; lysosomal acidification GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport
MFSD8 MFSD8/CLN7 Lysosomal MFS transporter; substrate not definitively assigned GO:0055085 transmembrane transport
ATP13A2 ATP13A2 Lysosomal polyamine (spermidine/spermine) export; P5B-ATPase GO:1902047 polyamine transmembrane transport; GO:0140326 ATPase-coupled intramembrane lipid transporter activity
GRN progranulin Loss of secreted lysosomal chaperone; prosaposin/cathepsin D regulation GO:0007040 lysosome organization

⚠️ GO IDs above are suggestions from domain knowledge and were not validated against OAK/OLS this session. Run just validate-terms before committing any of them.

Additional shared-process GO terms: GO:0007041 lysosomal transport; GO:0006914 autophagy; GO:0061919 process utilizing autophagic mechanism; GO:0006954 inflammatory response; GO:0050808 synapse organization; GO:0070997 neuron death. (Same validation caveat.)

6.4 Cross-gene interdependence

An important and under-modelled mechanism: NCL proteins regulate one another, so a single-gene lesion produces a multi-protein lysosomal deficit. "Loss of CLN3 has been shown to affect PPT1, TPP1, CLN5, and CTSD" (Zhang et al. 2025, PMID:39925015). CLN6 and CLN8 act as an obligate complex. Progranulin regulates prosaposin and cathepsin D. This explains both phenotypic convergence and why enzyme assays can be mildly abnormal in the "wrong" NCL.

6.5 Immune system involvement

Neuroinflammation, not autoimmunity or immunodeficiency. Microglial and astrocytic activation is early, regionally patterned, and in models precedes neuron loss: "Neuroimmune responses mediated by astrocytes and microglia are integral to the progression of neurodegenerative diseases" (PMID:39925015). Autoantibodies to GAD65 have been reported in CLN3 patients and provide the rationale for the immunosuppression trials in §12.4 — but CLN3 disease is not an autoimmune disease, and the entry should not be modelled as one.

Relevant CL terms: CL:0000129 microglial cell; CL:0000127 astrocyte; CL:0000540 neuron; CL:0000573 retinal cone cell; CL:0000604 retinal rod cell; CL:0000740 retinal ganglion cell; CL:0000121 Purkinje cell; CL:0000117 CNS neuron (sensu Vertebrata). (Not OAK-validated this session.)

6.6 Tissue damage mechanisms

Progressive neuronal death (apoptotic and non-apoptotic), synaptic loss preceding somatic loss, axonal/neuritic dystrophy, oxidative stress, and secondary mitochondrial dysfunction. Photoreceptor outer-segment degeneration precedes ganglion-cell loss in the retina. Reactive gliosis and progressive brain atrophy on MRI, most marked cerebellar and cortical.

6.7 Molecular profiling

  • Transcriptomics/proteomics/lipidomics: substantial data exist for CLN3 mouse and ovine CLN5/CLN6 models; human data are sparse. GEO/PRIDE hold NCL model datasets. Lipidomics is mechanistically important given the CLN5-BMP-synthase finding and the lipid nature of the storage material.
  • Single-cell / spatial: emerging in NCL mouse models (microglial state transitions); no established human single-cell atlas for any juvenile NCL member.
  • Functional genomics screens: DepMap and CRISPR screens have been used for CLN3 interactor discovery; nothing definitive at grouping level.

Honest statement for the KB: molecular-profiling evidence for MONDO:0019262 as a grouping is thin and almost entirely model-derived; gene-specific human omics is largely absent.

7. Anatomical Structures Affected

7.1 Organ level

Primary: - Central nervous system — UBERON:0001017 central nervous system; UBERON:0000955 brain; UBERON:0000956 cerebral cortex; UBERON:0002037 cerebellum; UBERON:0001897 dorsal thalamus / UBERON:0001879? (verify); UBERON:0002420 basal ganglia (verify); UBERON:0002240 spinal cord. - Eye / retina — UBERON:0000970 eye; UBERON:0000966 retina; UBERON:0001782 macula lutea (verify); UBERON:0000941 optic nerve (verify).

Secondary / systemic (storage is ubiquitous even where dysfunction is not): - Skin/eccrine sweat glands (the classic EM biopsy site), rectal mucosa, conjunctiva, skeletal muscle (granulovacuolar change in CTSD deficiency), peripheral blood lymphocytes (CLN3), myocardium (CLN3). - Body systems: nervous (primary), visual/sensory (primary), musculoskeletal (secondary — contractures, scoliosis), cardiovascular (CLN3-specific, late), respiratory (aspiration), digestive (dysphagia, malnutrition).

7.2 Tissue and cell level

Neural tissue is the target. Affected cell populations: retinal photoreceptors (rods and cones), retinal ganglion cells, cortical pyramidal neurons (layers II/III and V), cerebellar Purkinje cells and granule cells, thalamic relay neurons, with prominent involvement of microglia and astrocytes as active participants rather than bystanders. Storage material is also present in non-neural cells — fibroblasts, lymphocytes, eccrine gland epithelium — which is what makes peripheral biopsy diagnostically possible.

7.3 Subcellular level

  • GO:0005764 lysosome — the primary compartment.
  • GO:0005765 lysosomal membrane — locus of the transmembrane members (CLN3, MFSD8, ATP13A2).
  • GO:0005783 endoplasmic reticulum — locus of CLN6/CLN8.
  • GO:0005794 Golgi apparatus — the EGRESS trafficking route.
  • GO:0005776 autophagosome; GO:0005739 mitochondrion (SCMAS origin; secondary dysfunction); GO:0008021 synaptic vesicle (CSPα/CLN4, adult).

(GO CC IDs not OAK-validated this session.)

7.4 Localization and laterality

Bilateral and symmetric throughout. Retinopathy is bilateral; cerebral and cerebellar atrophy are symmetric. Asymmetry is not a feature and should prompt reconsideration of the diagnosis. The characteristic MRI pattern is early cerebellar atrophy with progressive generalised cerebral atrophy, periventricular white-matter T2 hyperintensity, and thalamic T2 hypointensity (best described in CLN2/late-infantile but seen across members).

8. Temporal Development

8.1 Onset

  • Age: the grouping's defining criterion — ~5–10 years, extended by some authors to 4–15 y. Practically: first symptom after the child has been developmentally normal through early schooling, and before the adult (>18 y) Kufs window.
  • Pattern: insidious and chronic-progressive. Not acute, not subacute. The apparent "sudden" presentation is usually delayed recognition of insidious visual loss.
  • Onset symptom by member: visual failure (CLN3, CLN5, CLN7, CLN10, many CLN1-juvenile) | seizures (CLN8/EPMR, many CLN6) | ataxia (TPP1-SCAR7, CLN6, CLN10) | parkinsonism (ATP13A2/CLN12) | behavioural/school problems (CLN3, frequently the true first sign in retrospect).

8.2 Progression and staging

A four-stage frame applies across the grouping (mapped most precisely for CLN3):

Stage Approx. age (CLN3) Features
I — Visual 4–7 y Rapid central vision loss, bull's-eye maculopathy, ERG abnormal → extinguished; behavioural/attention changes often already present
II — Cognitive/behavioural 6–12 y School failure, dementia onset, anxiety/psychosis, sleep disruption; blindness complete
III — Epileptic/motor 8–18 y Generalised tonic-clonic and myoclonic seizures; parkinsonism, dystonia, ataxia, dysarthria; ambulation lost
IV — End-stage late teens–20s/30s Bedbound, anarthric, dysphagic, gastrostomy-dependent; death from aspiration pneumonia/respiratory failure or status epilepticus

Formal instruments (CLN3-specific, not grouping-general): - Unified Batten Disease Rating Scale (UBDRS) — four subscales: physical (28 items, 0–112), seizure (12 items, 0–54), behaviour (9 items, 0–55), capability (5 items, 0–14). Validated in an independent CLN3 sample (PMC9879304). - CLN3 Disease Staging System (PMID:32300063). - CLN2 Clinical Rating Scale (Hamburg/Weill Cornell motor-language domains) — used as the primary endpoint in the cerliponase alfa trial.

There is no validated rating instrument for MONDO:0019262 as a whole; this is a real gap for any grouping-level natural-history or trial work.

8.3 Progression rate and course

Progression rate is genotype- and allele-dependent, and is the main axis of within-grouping variation: - Rapid: classic CLN3 (death typically third decade); juvenile CLN1 (faster than CLN3). - Intermediate: CLN6 juvenile, CLN5 juvenile, CLN10 juvenile. - Slow/protracted: TPP1-SCAR7 (ataxia only for decades); protracted MFSD8 (visual failure at 11, motor/seizures in mid-20s, mental/speech regression in the 30s); CLN8-EPMR (survival into middle age with seizure attenuation after puberty).

Course pattern: progressive, chronic, lifelong. No remission, spontaneous or treatment-induced, has ever been reported for any member. Disease duration: from onset to death, ~10–25 years for the classic members; longer for protracted forms.

8.4 Critical periods

  • Diagnostic window: the 1–3 years between visual failure and cognitive decline is the therapeutic opportunity. Diagnostic delay in this window is the norm and is the dominant modifiable failure in current care.
  • Therapeutic window: for the only disease-modifying therapy available (cerliponase alfa in CLN2), benefit is preservation of remaining function, not recovery — so the window closes as function is lost. The same logic applies to every gene therapy in trial. Zhang et al. put this bluntly: "these therapies are unlikely to achieve partial disease reversal, and complete reversal remains improbable."
  • Presymptomatic identification (sibling cascade testing) is currently the only route to treatment before loss.

9. Inheritance and Population

9.1 Epidemiology

Grouping-level, from the Scandinavian survey (Neuropediatrics 1997;28(1):6-8; PMID:9151309) — the best direct data on juvenile NCL as such:

"For juvenile NCL 40 Swedish living patients were identified. The corresponding number for Finland was 61, for Norway 28, for Denmark 16 and for Iceland three. The prevalence of juvenile NCL was thus 4.6, 12.2, 6.5, 3.1 and 11 per million inhabitants in Sweden, Finland, Norway, Denmark, and Iceland, respectively. For calculating incidence the years 1976-85 were used. The incidence was 2.2 per 100,000 live births in Sweden, 4.8 in Finland, 3.7 in Norway, 2.0 in Denmark, and 7.0 in Iceland."

Structured for curation:

Population Measure Value rate_per_100000
Sweden Point prevalence 4.6 / 1,000,000 0.46
Finland Point prevalence 12.2 / 1,000,000 1.22
Norway Point prevalence 6.5 / 1,000,000 0.65
Denmark Point prevalence 3.1 / 1,000,000 0.31
Iceland Point prevalence 11 / 1,000,000 1.10
Sweden Birth prevalence / incidence (1976–85) 2.2 / 100,000 live births 2.2
Finland Birth prevalence / incidence 4.8 / 100,000 live births 4.8
Norway Birth prevalence / incidence 3.7 / 100,000 live births 3.7
Denmark Birth prevalence / incidence 2.0 / 100,000 live births 2.0
Iceland Birth prevalence / incidence 7.0 / 100,000 live births 7.0

Italy (Orphanet J Rare Dis 2013;8:19; PMID:23374165), a contrasting low-incidence population, and directly informative about the juvenile fraction:

"One hundred eighty-three NCL patients from 156 families were recruited between 1966 and 2010… Late infantile onset NCL (LINCL) accounted for 75.8% of molecularly confirmed cases, the most frequent form being secondary to mutations in CLN2 (23.5%). Juvenile onset NCL patients accounted for 17.7% of this cohort, a smaller proportion than found in other European countries. … An incidence rate of 0.98/100,000 live births was found in 69 NCL patients born between 1992 and 2004, predicting 5 new cases a year. Prevalence was 1.2/1,000,000."

All-NCL range (Gene 2016, PMID:27553520): "Estimates of NCL incidence range from 0.6 to 14 per 100,000 live births but vary widely between populations."

Synthesis: juvenile NCL is best characterised as ~2–5 per 100,000 live births in Northern Europe, ~0.2–1 per 100,000 in Southern Europe, with point prevalence of roughly 0.3–1.2 per 100,000 population. In Orphanet prevalence-class terms this is BAND_1_9_PER_1000000 for point prevalence in most European populations. The juvenile fraction of all NCL ranges from ~18% (Italy) to a majority in Northern Europe.

9.2 Inheritance genetics

  • Pattern: autosomal recessive for every defensible member. HPO HP:0000007 Autosomal recessive inheritance. (The one AD NCL, DNAJC5/CLN4, is adult-onset and excluded.)
  • Penetrance: complete for biallelic pathogenic genotypes. No reported non-penetrant biallelic carriers.
  • Expressivity: variable, including within families sharing a genotype (documented in the Chinese CLN6 sibship, PMID:35609511). Age of onset and MRI severity varied between siblings with the identical homozygous missense variant.
  • Anticipation: not applicable — no repeat-expansion mechanism in any NCL gene.
  • Germline mosaicism: not documented as a recurrence mechanism; recurrence risk for AR members is the standard 25%. Note the de novo p.Tyr295Cys CLN6 allele in Cypriot family 926 (PMID:34868216) — a de novo event on one allele in an otherwise recessive disorder, which alters recurrence counselling for that family.
  • Consanguinity: a major contributor. Homozygosity for private missense alleles in consanguineous pedigrees is the modal route to the non-CLN3 juvenile forms (Cypriot, Chinese, Somali, Turkish, Roma reports).
  • Carrier frequency: PPT1 1/75 in Finns; PPT1, TPP1, CLN3 each ~1/500 US-adjusted (PMID:27553520).

9.3 Population demographics and geography

Population Enriched gene / allele Note
Finland CLN8 p.Arg24Gly (EPMR, Kainuu region); CLN5 p.Tyr392*; PPT1 p.Arg122Trp Finnish disease heritage; highest juvenile NCL prevalence in the Scandinavian survey
Northern/Western European ancestry CLN3 1.02-kb deletion The dominant juvenile NCL allele worldwide by count
Roma (former Czechoslovakia) MFSD8 p.Thr294Lys 14 patients from 12 families, founder effect (PMID:19201763)
Turkey MFSD8, CLN8, CLN6 Overrepresented in vLINCL series; high consanguinity
Newfoundland multiple Distinct genetic epidemiology (Clin Genet 2008; PMID:18684116)
Greek-Cypriot CLN6 p.Arg136His Juvenile onset without visual loss (PMID:34868216)
Somali CTSD p.Gly149Val Juvenile CLN10 sibship
South America / Caribbean mixed Regional overview: Front Neurol 2022 (PMID:36034292)
Russia CLN spectrum incl. novel alleles Mol Genet Genomic Med 2020 (PMID:32412666)
  • Sex ratio: 1:1. Autosomal recessive; no sex bias in incidence. (The Cypriot CLN6 series happened to be all male — a chance finding in n=3, not a sex effect.)
  • Age distribution of affected individuals: by definition onset 5–10 y; the prevalent population spans childhood through the third decade (longer for protracted members).

10. Diagnostics

10.1 The diagnostic algorithm for a suspected juvenile NCL

This is the practical heart of the entity, and it is genuinely different from the CLN3-only algorithm.

Step 1 — Recognise the syndrome. School-age child with progressive visual failure + retinal dystrophy, or new-onset epilepsy with cognitive regression, or progressive ataxia with cognitive decline.

Step 2 — Enzyme assays first (fast, cheap, and immediately actionable). In leukocytes, fibroblasts, or dried blood spot: - TPP1 (CLN2) — do this first: it is the only NCL with an approved therapy. - PPT1 (CLN1) — will catch juvenile CLN1, which EM would mislabel as infantile. - Cathepsin D (CLN10).

A normal result on all three excludes three of the nine defensible members in days.

Step 3 — Blood film for vacuolated lymphocytes. Positive → strongly suggests CLN3. Cheap, immediate, and one of the few within-grouping discriminators available at the bedside.

Step 4 — Molecular testing. Targeted CLN3 common-deletion PCR if the phenotype is classic; otherwise, and in all enzyme-negative cases, a multigene NCL panel covering at minimum PPT1, TPP1, CLN3, DNAJC5, CLN5, CLN6, MFSD8, CLN8, CTSD, GRN, ATP13A2, CTSF, KCTD7. Exome or genome sequencing where panel is negative or where the differential is broader (juvenile-onset ataxia, PME, or retinal dystrophy differentials). GTR lists dedicated NCL/Batten panels. - Copy-number analysis must be included — the CLN3 1.02-kb deletion and multi-exon deletions in other NCL genes are missed by SNV-only pipelines. - A known WES failure mode: in-frame duplications can be missed by both Sanger and WES through allelic dropout — the DNAJC5 case in PMID:31919451. Reanalysis of raw WES data with modified protocols recovered it.

Step 5 — Electron microscopy (skin/conjunctival/rectal biopsy) is now second-line but retains value in molecularly unsolved cases. Interpret ultrastructure as a pointer to the gene, not to the onset class (§4.2).

10.2 Ultrastructural patterns (GeneReviews Table 2)

Pattern Genes
GROD (granular osmiophilic deposits) PPT1, CTSD, DNAJC5, (+CTSF)
Curvilinear TPP1, (+CLN3, CLN5, CLN6, GRN, KCTD7)
Fingerprint CLN3, MFSD8, GRN, CTSF, KCTD7, (+CLN5, CLN6)
Rectilinear CLN5, CLN6, MFSD8, CLN3, KCTD7
Curvilinear-like fingerprint, granular CLN8
Mixed (GROD + others) CLN6 adult

10.3 Imaging, electrophysiology, and other tests

  • MRI brain: cerebellar atrophy (early and often disproportionate), progressive generalised cerebral atrophy, periventricular T2 white-matter hyperintensity, thalamic T2 hypointensity. In one CLN6 sibship MRI severity diverged sharply between siblings with an identical genotype (PMID:35609511) — MRI is not a reliable genotype predictor.
  • ERG: abnormal early, becomes extinguished; often the finding that first raises "retinal dystrophy" before the neurological diagnosis. HP:0000512 → HP:0000550.
  • OCT / fundus autofluorescence: retinal thinning, outer-retinal loss, abnormal autofluorescence (HP:0030602).
  • VEP: enlarged/giant responses early (as in other PMEs), attenuating later.
  • EEG: progressive slowing; generalised epileptiform discharges; photoparoxysmal response at low flash frequencies is a classic PME/NCL clue.
  • Nerve conduction: may show sensory axonal neuropathy (CTSD; PMID:25298308).
  • Muscle biopsy: not routine, but in CTSD deficiency shows "granulovacuolar material in angular atrophic fibers in addition to the granular osmiophilic deposits" (PMID:25298308).
  • CSF neurofilament light chain: an emerging progression biomarker in NCL — not validated for diagnosis; do not curate as a diagnostic test.

LOINC coding exists for the enzyme assays and for ERG; ⚠️ specific LOINC codes were not retrieved this session.

10.4 Omics-based diagnostics

  • RNA sequencing has a real role: resolving splice-region VUS in NCL genes (functional splicing evidence for ACMG PS3/BS3). Worth curating as an adjunct, not a first-line test.
  • Proteomics / metabolomics / liquid biopsy: no validated clinical diagnostic role for any NCL.
  • Epigenomics: no role.

10.5 Clinical criteria and differential diagnosis

There are no formal consensus diagnostic criteria for "juvenile NCL" as a grouping. Diagnosis is by demonstration of a biallelic pathogenic genotype in an NCL gene, with a compatible juvenile-onset phenotype (and, historically, characteristic storage on EM).

Differential diagnosis, organised by presenting syndrome — this is where the grouping earns its keep:

Presentation Consider within the grouping Consider outside
Juvenile visual failure + maculopathy CLN3, CLN5, CLN7/MFSD8, CLN10, juvenile CLN1 Stargardt disease (ABCA4), cone-rod dystrophy, retinitis pigmentosa, Leber hereditary optic neuropathy, non-syndromic MFSD8 maculopathy
Juvenile epilepsy + regression CLN6, CLN8/EPMR, CLN3, CLN2-juvenile Lafora disease (EPM2A/NHLRC1), Unverricht-Lundborg (CSTB), MERRF, sialidosis, Gaucher type 3, juvenile Huntington disease, DRPLA, SSPE
Juvenile progressive ataxia TPP1-SCAR7, CLN5, CLN6, CLN10 Friedreich ataxia, ataxia-telangiectasia, AOA1/2, Niemann-Pick type C, mitochondrial ataxias
Juvenile parkinsonism ATP13A2/CLN12 PRKN/PINK1/DJ-1 juvenile parkinsonism, Wilson disease, PKAN/NBIA, dopa-responsive dystonia
Juvenile dementia + psychosis CLN3 Niemann-Pick type C (a critical and treatable-adjacent mimic), Wilson disease, juvenile Huntington, subacute sclerosing panencephalitis, mitochondrial disease

Niemann-Pick type C and Wilson disease deserve specific mention as the two mimics where missing the diagnosis has the greatest therapeutic cost.

10.6 Screening

  • Newborn screening: not implemented anywhere for any NCL. TPP1 enzyme activity in dried blood spot is technically NBS-compatible and has been piloted; the argument for it strengthened materially once cerliponase alfa was approved, but it targets CLN2 (predominantly late-infantile), not the juvenile grouping. Adding NCL to RUSP-type panels remains an open policy question.
  • Carrier screening: available for known familial variants; expanded carrier-screening panels increasingly include CLN3, PPT1, TPP1. Population carrier screening is not recommended outside founder populations.
  • Cascade screening of siblings is the highest-yield screening activity, because it can identify a presymptomatic sibling within the therapeutic window.

11. Outcome / Prognosis

11.1 Survival and mortality

  • Uniformly fatal for the classic members. No cure exists for any form.
  • CLN3: life expectancy typically second to third decade; deaths reported from late teens into the 30s and occasionally 40s.
  • Juvenile CLN1: generally more rapid than CLN3.
  • Protracted members (TPP1-SCAR7, protracted MFSD8, CLN8-EPMR): survival into the fourth to sixth decade, with EPMR patients reaching middle age.
  • Mortality mechanisms: aspiration pneumonia (the leading cause), respiratory failure, status epilepticus, and — in CLN3 specifically — cardiac arrhythmia/conduction disease in the second-to-third decade.
  • ⚠️ No formal 5-/10-year survival statistics exist for the grouping. There is no SEER-equivalent registry. Any percentage survival figure encountered in the literature is almost certainly CLN3-specific and cohort-specific — do not generalise it to MONDO:0019262.

11.2 Morbidity and function

Profound and cumulative: blindness → dementia → epilepsy → loss of ambulation → loss of speech → gastrostomy dependence → total care dependence. Effectively 100% disability by the end of the second decade in the classic members. Very high caregiver burden; the psychiatric phase in CLN3 adolescence is repeatedly reported as the hardest for families.

Quality-of-life instruments: no NCL-specific validated QoL instrument is in general use. Generic pediatric instruments (PedsQL, EQ-5D-Y) are poorly suited once vision and cognition are lost. The UBDRS capability subscale is the closest available functional measure and is CLN3-validated only. This is a documented measurement gap, and the honest curation statement is that grouping-level QoL data do not exist.

11.3 Complications

Status epilepticus; aspiration pneumonia; malnutrition and failure to thrive; contractures and neuromuscular scoliosis; osteopenia/fractures; pressure injury; sleep disorder; behavioural crisis and psychosis; in CLN3, cardiac conduction disease and arrhythmia; drug-refractory epilepsy.

11.4 Recovery potential

None. No spontaneous or treatment-induced remission has been described. Even the best-evidenced disease-modifying therapy (cerliponase alfa) slows decline rather than reversing it — a point the field states plainly (Zhang et al., PMID:39925015). Rehabilitation preserves function and comfort but does not alter trajectory.

11.5 Prognostic factors

  • Genotype is the dominant prognostic factor, and is the strongest argument for pursuing molecular diagnosis even when it does not change treatment: it changes the prognosis conversation from "second-to-third decade" (CLN3) to "possibly middle age" (EPMR, SCAR7, protracted MFSD8).
  • Allele severity within a gene: null/null → earlier onset and faster decline; hypomorph in trans → later onset, slower decline (the TPP1 CLN2-vs-SCAR7 dichotomy is the cleanest demonstration).
  • Age at onset: earlier onset predicts faster progression, consistently across members.
  • Seizure control and nutritional/respiratory management are the main modifiable prognostic factors.
  • Prognostic biomarkers: none validated. CSF NfL and MRI volumetrics are under investigation.

12. Treatment

Overarching statement: there is no approved disease-modifying therapy for MONDO:0019262 as a grouping. There is exactly one approved disease-modifying therapy for one member gene (TPP1/CLN2), and a set of gene therapies in trial. Everything else is symptomatic and supportive.

12.1 Enzyme replacement therapy — TPP1/CLN2 only

Cerliponase alfa (Brineura) — recombinant human TPP1 delivered by intracerebroventricular infusion via an implanted reservoir, 300 mg every 2 weeks. Approved by FDA (2017) and EMA for CLN2 disease. Pivotal evidence:

"The mean (±SD) unadjusted rate of decline in the motor-language score per 48-week period was 0.27±0.35 points in treated patients and 2.12±0.98 points in 42 historical controls." — Schulz A et al. "Study of Intraventricular Cerliponase Alfa for CLN2 Disease." N Engl J Med 2018;378(20):1898-1907 (PMID:29688815)

The trial enrolled 24 children aged 3–16, all receiving 300 mg for at least 96 weeks; median time to a 2-point motor-language decline was not reached in treated patients versus 345 days in controls (P<0.001). Adverse events: convulsions, fever, vomiting, hypersensitivity reactions; two patients developed device-related infections requiring antibiotic therapy and device replacement.

Relevance to this entity: the age range 3–16 y means the trial population included juvenile-onset CLN2 patients. Any child in the juvenile window with a compatible phenotype should have a TPP1 assay early, because this is the one branch of the differential with an approved therapy. This single fact is the strongest clinical justification for modelling MONDO:0019262 as gene-heterogeneous rather than as CLN3.

  • NCIT: NCIT:C15986 Pharmacotherapy; NCIT:C158784? (a specific cerliponase alfa NCIT code likely exists but was not verified this session). therapeutic_modality: PROTEIN_REPLACEMENT.
  • ERT is not extensible to the transmembrane members (CLN3, CLN6, MFSD8, CLN8, ATP13A2) — there is no soluble enzyme to replace. Zhang et al.: ERT is "limited to soluble lysosomal enzyme deficiencies due to blood-brain barrier challenges."

12.2 Gene therapy (investigational)

AAV-vectored gene transfer, largely AAV9 by intrathecal or intracerebroventricular route. Trials have been run or are running for CLN2, CLN3, CLN5, CLN6, and CLN7:

Target Trial Notes
CLN3 NCT03770572 Phase 1/2, open-label, single-dose, dose-escalation; intrathecal AAV9 (AT-GTX-502 / CLN-301); low- and high-dose cohorts, 5-year follow-up
CLN6 NCT02725580 Phase 1/2 intrathecal scAAV9.CB.CLN6 for variant late-infantile CLN6
CLN6 NCT07582484 Phase 1/2b, scAAV9-delivered CLN6; estimated start August 2026
CLN7/MFSD8 first-in-human high-dose AAV9 intrathecal, phase 1 open-label single ascending dose (published; PMC12703863)
CLN5 natural-history study NCT03822650 underpinning trial design

Preclinical support is strongest where large-animal models exist: intracerebroventricular scAAV9.CB.CLN6 "significantly alleviates motor defects, delays learning and memory impairment, and extends lifespan" (reviewed in PMID:39925015), and the naturally occurring ovine CLN5/CLN6 models have carried much of the translational work (§15).

NCIT: NCIT:C15238 Gene Therapy; therapeutic_modality: GENE_THERAPY.

12.3 RNA-based therapy

Milasen — the landmark n-of-1 patient-customised splice-modulating antisense oligonucleotide, designed against a cryptic splice-acceptor site created by a MFSD8/CLN7 retrotransposon insertion, designed, manufactured, and dosed within about a year (Kim J et al., N Engl J Med 2019;381:1644-1652). ⚠️ The PMID for this paper could not be confirmed by the searches run this session — verify before citing. Referenced in the 2025 review as "Milasen, designed to target…cryptic splice-acceptor site" (PMID:39925015).

Significance for this entity: milasen is the proof of concept that a private allele in a rare member of this grouping can be drugged, and is a strong argument for exact molecular diagnosis rather than a syndromic "juvenile NCL" label.

NCIT: NCIT:C15986; therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE; aso_mechanism: SPLICE_MODULATION_EXON_INCLUSION (mechanism assignment should be confirmed against the primary paper).

12.4 Other investigational and repurposed approaches

  • Miglustat — substrate-reduction agent; open-label safety/PK/efficacy study in CLN3 (NCT05174039).
  • Mycophenolate mofetil — immunosuppression rationale from the autoimmune/neuroinflammatory arm of CLN3 pathogenesis (NCT01399047).
  • Small molecules: NtBuHA (a cysteamine-derived thioesterase mimetic, CLN1), trehalose (autophagy inducer), gemfibrozil (PPARα agonist) — all preclinical/early (PMID:39925015).
  • Hematopoietic stem-cell gene therapy: "Overexpressing PPT1 on hematopoietic stem cells… has been shown to extend the lifespan of CLN1-deficient mice" (PMID:39925015). Unmodified HSCT has not shown benefit in NCL and should not be offered.
  • Microglial replacement therapies — an emerging concept given the centrality of neuroinflammation.
  • Investigations of Juvenile Neuronal Ceroid Lipofuscinosis — NCT03307304; Natural History Study of Batten Disease — NCT04644549.

12.5 Symptomatic and supportive care (the mainstay)

Domain Intervention NCIT
Epilepsy Levetiracetam, valproate, lamotrigine, clobazam, zonisamide. Myoclonus: levetiracetam, piracetam, clonazepam NCIT:C15986 Pharmacotherapy
⚠️ Drugs to avoid Carbamazepine, oxcarbazepine, phenytoin, and (per PME practice) vigabatrin/tiagabine/gabapentin may aggravate myoclonus and myoclonic seizures in progressive myoclonic epilepsies including NCL. This is an actionable prescribing caution worth curating explicitly. —
Movement disorder Trihexyphenidyl, baclofen, botulinum toxin for dystonia; levodopa trial in ATP13A2/CLN12 parkinsonism NCIT:C15986
Psychiatric Risperidone/other atypical antipsychotics for psychosis and agitation; SSRIs for anxiety NCIT:C15986
Sleep Melatonin NCIT:C15986
Vision Low-vision services, braille and orientation/mobility training, assistive technology — initiate early, before cognitive decline forecloses learning NCIT:C15315 Rehabilitation
Nutrition Dysphagia assessment, thickened feeds, gastrostomy NCIT:C15433 Nutritional Support; NCIT:C15329 Surgical Procedure
Respiratory Chest physiotherapy, suctioning, aspiration precautions, vaccination NCIT:C15747 Supportive Care
Musculoskeletal Physical and occupational therapy, seating/positioning, scoliosis surveillance and management NCIT:C15302 Physical Therapy; NCIT:C121351 Occupational Therapy
Communication Speech and language therapy; AAC before speech is lost NCIT:C159273 Speech Therapy
Cardiac (CLN3) ECG/Holter surveillance from adolescence; pacemaker in selected cases NCIT:C15747
Family Genetic counselling NCIT:C15240 Genetic Counseling
End of life Palliative care, advance care planning NCIT:C15747 Supportive Care

12.6 Pharmacogenomics

No NCL-specific pharmacogenomic guidance exists. Standard CPIC guidance applies to the drugs used (e.g. HLA-B*15:02 and carbamazepine — moot here, since carbamazepine is relatively contraindicated; CYP2C9/CYP2C19 for valproate/clobazam metabolism). PharmGKB has no NCL-specific entries.

12.7 Treatment strategy

The algorithm is short and genotype-gated:

  1. Establish the gene. Enzyme assays → panel/WES → CNV analysis.
  2. If TPP1/CLN2 → refer for cerliponase alfa immediately. This is the only branch with an approved therapy, and benefit depends on remaining function.
  3. If another member → assess trial eligibility (CLN3 NCT03770572, CLN6 NCT02725580/NCT07582484, CLN7 AAV9, CLN5 natural history) and enrol in natural-history registries.
  4. In all cases → multidisciplinary symptomatic care (neurology, ophthalmology/low vision, epileptology, gastroenterology/nutrition, rehabilitation, palliative care, genetics).
  5. In all cases → sibling cascade testing, to catch a presymptomatic sibling while the therapeutic window is open.

13. Prevention

  • Primary prevention: not possible. These are germline monogenic disorders. No vaccination, no risk-factor modification, no behavioural intervention affects occurrence. Curate this section as explicitly not-applicable rather than inventing content.
  • Reproductive prevention is the only route that reduces incidence:
  • Genetic counselling (NCIT:C15240) — 25% recurrence risk for AR members; discussion of consanguinity where relevant.
  • Carrier testing of at-risk relatives once the familial variants are known.
  • Prenatal diagnosis (CVS/amniocentesis) and preimplantation genetic testing for monogenic disease (PGT-M) — both routine once the biallelic genotype is defined.
  • Population carrier screening in founder populations (Finland; Roma communities for MFSD8 p.Thr294Lys) is technically justifiable; consanguineous-community screening programmes are the highest-yield setting.
  • Secondary prevention (early detection):
  • Cascade testing of siblings — the single highest-value preventive act, and the only one that can place a child in the therapeutic window.
  • Newborn screening — not implemented; TPP1 dried-blood-spot assay is the leading candidate now that CLN2 is treatable. This is a live policy question, not current practice.
  • Awareness-driven earlier diagnosis: an ophthalmologist encountering a school-age child with rapidly progressive maculopathy and an abnormal ERG should consider NCL, not stop at "Stargardt". Diagnostic-delay reduction is the most tractable secondary-prevention target for this entity.
  • Tertiary prevention (complication avoidance): seizure-medication optimisation with avoidance of myoclonus-aggravating agents; dysphagia surveillance and timely gastrostomy to prevent aspiration; scoliosis and contracture surveillance; cardiac surveillance in CLN3; vaccination and respiratory care.
  • Public health / environmental interventions: not applicable.

14. Other Species / Natural Disease

NCL is one of the best examples in medicine of a human rare disease with naturally occurring, breed-defined large-animal counterparts — which is why NCL gene therapy has an unusually strong translational pipeline.

14.1 Taxonomy and natural disease

Species NCBITaxon Gene(s) Notes
Dog (Canis lupus familiaris) NCBITaxon:9615 TPP1, CLN5, CLN6, CLN8, ATP13A2, PPT1, ARSG, CNP, MFSD8 OMIA:000181-9615 "Neuronal Ceroid Lipofuscinosis, generic in Canis lupus familiaris"; numerous breed-specific gene entries
Sheep (Ovis aries) NCBITaxon:9940 CLN5 (Borderdale), CLN6 (South Hampshire, Merino) The premier large-animal models; used for MRI-based longitudinal studies and gene-therapy proof of concept
Cattle (Bos taurus) NCBITaxon:9913 CLN5 Devon cattle
Cat, goat, horse — various Sporadic reports
Mouse (Mus musculus) NCBITaxon:10090 Cln8 (mnd, naturally occurring), plus engineered alleles The mnd mouse was identified as a natural Cln8 mutant in the same paper that cloned human CLN8

Breeds (VBO): Tibetan Terrier (ATP13A2/CLN12; onset 4–6 y, i.e. adult-equivalent in dog terms), American Staffordshire Terrier (ARSG, an NCL-like disorder with no confirmed human juvenile NCL counterpart — ARSG in humans causes Usher syndrome type IV), Border Collie and Golden Retriever (CLN5), Australian Shepherd and Schapendoes (CLN6), English Setter (CLN8), Dachshund (TPP1, PPT1), Miniature Schnauzer, Chihuahua. ⚠️ Specific VBO identifiers were not retrieved this session.

Veterinary importance: canine NCL is a genuine clinical veterinary disease with commercial DNA tests offered by breed clubs for carrier avoidance — a real-world instance of the carrier-screening logic in §13. Border Collie NCL in Japan has been the subject of a dedicated molecular-epidemiological study (PMID:22919312).

14.2 Orthologous genes

All human NCL genes have well-conserved orthologues across mammals; PPT1, TPP1, CTSD, CLN3, CLN5, CLN6, CLN8, MFSD8, and ATP13A2 orthologues exist in mouse, rat, dog, sheep, and (for most) zebrafish and Drosophila. Alliance of Genome Resources and HomoloGene are the reference sources; ⚠️ specific NCBI Gene IDs were not retrieved this session.

14.3 Comparative biology

  • Conservation of mechanism is high: lysosomal storage, SCMAS accumulation, autofluorescence, neuroinflammation, and retinal plus CNS neurodegeneration recur across species. Ranta et al. put the CLN8/mnd correspondence as "the first description of the molecular basis of a naturally occurring animal model for NCL" (PMID:10508524).
  • Key comparative divergence: disease tempo and retinal involvement differ. Ovine CLN5/CLN6 recapitulate retinal degeneration well (PMC8901734 — natural history of retinal degeneration in ovine CLN5/CLN6) and brain atrophy is trackable by MRI (PMC9830986); rodent models often under-recapitulate the retinal phenotype that dominates the human juvenile presentation.
  • Zoonotic potential / cross-species transmission: none. Genetic disease; not transmissible.

15. Model Organisms

15.1 Mouse (Mus musculus, NCBITaxon:10090) — MGI, IMPC, IMSR, JAX

Model Type Recapitulation Limitations
Cln3Δex7/8 knock-in Knock-in of the human common 1.02-kb deletion The most translationally faithful CLN3 model: storage, autofluorescence, gliosis, motor decline Mild and late relative to human; poor retinal phenotype; near-normal lifespan — so it does not model the defining human feature (juvenile blindness) or lethality
Cln3−/− Knockout Storage, neuroinflammation Same mildness problem
Ppt1−/− Knockout GROD storage, seizures, retinal degeneration, shortened lifespan Models infantile CLN1, not juvenile CLN1
Tpp1/Cln2 mouse Knockout Good phenotypic fidelity; used for cerliponase alfa development Models late-infantile CLN2
Cln5−/− Knockout Storage, gliosis, visual dysfunction Mild motor phenotype
Cln6nclf Spontaneous frameshift Storage, retinal degeneration, motor decline, shortened lifespan — a good model Late-infantile-equivalent tempo
Cln8mnd (motor neuron degeneration) Naturally occurring 1-bp insertion (267-268insC, codon 90) Retinal degeneration, motor neuron degeneration, storage Was the model that enabled human CLN8 cloning (PMID:10508524)
Mfsd8/Cln7−/− Knockout Storage, retinal and CNS degeneration Used for AAV9/MFSD8 preclinical work
Ctsd−/− Knockout Severe, early-lethal (~postnatal day 26) with GROD Models congenital CLN10, not juvenile
Grn−/− Knockout "Reexamination of progranulin-deficient mice revealed rectilinear profiles typical of NCL" (PMID:22608501) Lipofuscinosis without frank early neurodegeneration; models the homozygous-GRN NCL better than it models FTLD
Atp13a2−/− Knockout Lipofuscinosis, gliosis, mild motor No robust nigral dopaminergic loss — a major limitation for the KRS/parkinsonism phenotype
Kctd7−/−, Ctsf−/−, Dnajc5 models Various Partial

Conditional and cell-type-specific alleles exist for several (notably Cln3 and Ppt1), enabling dissection of the neuron-vs-glia contribution to neuroinflammation.

Cross-cutting mouse limitation, stated honestly: the mouse models under-recapitulate the two features that define the human juvenile phenotype — early profound visual failure and death in the second-to-third decade. A dismech entry should record this as a HUMAN_MODEL_MISMATCH discussion rather than a generic knowledge gap: the evidence exists in the model, but its translational validity for the juvenile-onset human phenotype is the open question.

15.2 Large animals — the translational workhorses

  • Sheep: the Borderdale CLN5 and South Hampshire / Merino CLN6 flocks (New Zealand) are naturally occurring, well-characterised, and gyrencephalic with a brain size and lifespan permitting realistic dosing, surgical delivery, and longitudinal imaging. Published resources include progressive MRI brain-volume studies (PMC9830986) and natural-history studies of retinal degeneration (PMC8901734). These models carry much of the credibility of the CLN5/CLN6 gene-therapy programmes.
  • Dog: TPP1 Dachshund, CLN5 Border Collie/Golden Retriever, CLN6 Australian Shepherd/Schapendoes/mixed-breed, CLN8 English Setter, ATP13A2 Tibetan Terrier. The Dachshund TPP1 model contributed to ERT development.
  • Cattle: Devon CLN5.

15.3 Non-mammalian and in vitro

  • Zebrafish (Danio rerio, NCBITaxon:7955) — ZFIN; cln3, mfsd8, ppt1, tpp1 morphants/mutants. Value: rapid, optically transparent, well-suited to retinal phenotyping and small-molecule screening — arguably the best system for the visual arm of this grouping.
  • Drosophila melanogaster (NCBITaxon:7227) — FlyBase; Cln3, Ppt1, Cln7 models for genetic-modifier screens.
  • C. elegans, yeast — used for CLN3 and MFSD8 orthologue function.
  • Patient-derived fibroblasts — the practical workhorse for enzyme assays and storage-material characterisation; the substrate for the CTSD activity measurements in PMID:25298308.
  • iPSC-derived neurons, cerebral organoids, and retinal organoids — the most promising human-relevant systems, and the only ones that can model the human-specific retinal vulnerability. Retinal organoids are particularly apt here given the vision-first phenotype.

15.4 Applications

Mechanism dissection (lysosomal storage, autophagy, neuroinflammation), biomarker discovery, preclinical efficacy and safety for AAV gene therapy and ERT, dose-finding and route-of-administration studies (large animals), and high-throughput drug screening (zebrafish, iPSC).

15.5 Resources

MGI, IMPC/KOMP, IMSR, JAX, EMMA, MMRRC (mouse); RGD (rat); ZFIN (zebrafish); FlyBase; WormBase; OMIA (OMIA:000181 and gene-specific entries) for natural animal disease; Alliance of Genome Resources for orthology; Cellosaurus/ATCC and Coriell (NIGMS repository holds NCL patient fibroblast lines) for cell models; the UCL NCL Resource (ucl.ac.uk/ncl-disease) for the mutation and patient database.

16. Curation guidance and verification status

16.1 The three claims this entry must make that a CLN3-anchored entry would not

  1. At least nine genes — CLN3, PPT1, TPP1, CLN5, CLN6, MFSD8, CLN8, CTSD, ATP13A2 — have defensible juvenile-onset presentations. CLN3 is the most prevalent, not the definition.
  2. Vision loss is typical but not necessary. CLN8/EPMR and several CLN6 juvenile families present without visual failure. A definition requiring retinopathy would wrongly exclude real members.
  3. Onset class and gene are orthogonal axes. The same gene can appear in the juvenile, late-infantile, and adult groupings via different alleles — CLN6 spans all three. This is not an inconsistency to be resolved; it is the structure of the domain.

16.2 Members to exclude, and why

Gene Reason for exclusion
DNAJC5/CLN4 Autosomal dominant, adult-onset Kufs. No juvenile phenotype.
CTSF/CLN13 Adult Kufs type B. Onset >20 y.
KCTD7/CLN14 Infantile/late-infantile PME.
GRN/CLN11 "Teenage to adult" per GeneReviews; typical onset ~20–25 y. Adjacent, not a member.
"CLN9" Withdrawn. No gene. The index family was reassigned to CLN5. Present in MONDO only as a legacy artefact.

16.3 Ontology defects observed (worth reporting upstream)

  1. MONDO:0019262 asserts only five children (MONDO:0979341 CLN1, MONDO:0979345 CLN2, MONDO:0979346 CLN3, MONDO:0012188 "NCL 9", MONDO:0017809 ATP13A2), while the literature supports at least nine members. CLN5, CLN6, CLN7/MFSD8, CLN8, and CLN10 juvenile forms have no corresponding MONDO term.
  2. MONDO:0012188 ("neuronal ceroid lipofuscinosis 9") is asserted as a child of the juvenile grouping despite CLN9 being a withdrawn designation whose index family was reassigned to CLN5.
  3. The synonym overlap with MONDO:0008767 (Vogt Spielmeyer disease, Spielmeyer Sjogren disease, Batten disease) is the mechanical driver of the historical conflation and is worth flagging even though it accurately reflects historical usage.
  4. MONDO:0979346 is correctly dual-parented (MONDO:0019262 + MONDO:0008767) but was not returned by the OLS4 /descendants endpoint — a retrieval inconsistency that could cause an automated member-enumeration script to silently miss the CLN3 member.

16.4 Verification status of citations in this report

Fully transcribed abstracts (single-PMID E-utilities fetch; quotes in this report are verbatim from those transcriptions): PMID:21990111 · PMID:10508524 · PMID:31919451 · PMID:34868216 · PMID:35609511 · PMID:27553520 · PMID:23374165 · PMID:9151309 · PMID:22608501 · PMID:25227500 · PMID:22388936 · PMID:29688815

Partial quotes only (fragments returned inside multi-record fetches or PMC full-text extraction; the quoted strings are reliable but the surrounding abstract was summarised): PMID:22778232 · PMID:9425237 · PMID:23418007 · PMID:20157158 · PMID:19201763 · PMID:39281238 · PMID:25298308 · PMID:26026925 · PMID:39925015

Cited but PMID or content NOT verified this session — verify before curating as evidence: - Wisniewski KE et al., "Reevaluation of neuronal ceroid lipofuscinoses: atypical juvenile onset may be the result of CLN2 mutations", Mol Genet Metab 1999 (exact-title query returned no results) - International Batten Disease Consortium, "Isolation of a novel gene underlying Batten disease, CLN3", Cell 1995 (author/title queries returned no results) - Kim J et al., "Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease" (milasen), NEJM 2019 - El Haddad et al. 2012, reassignment of the CLN9 family to CLN5 - Tyynelä et al., saposins A and D as the stored proteins in CLN1/CLN10 - The CLN3 1.02-kb deletion allele frequencies (~80–85% of alleles; ~70–75% homozygous) - ICD-10 E75.4 assignment - All GO, CL, UBERON, CHEBI, and NCIT identifiers suggested in this report, and HP:0001922 (vacuolated lymphocytes) and HP:0011675 (arrhythmia), which were not found in the local HP cache

Verified against the local cache/hp/terms.csv: every HP identifier in §3 other than HP:0001922 and HP:0011675.

For dismech curation specifically: every PMID cited here must go through just fetch-reference PMID:XXXXXXXX, and every snippet through just count-verified-snippets, before it enters a kb/disorders/ entry. Several of the quotes above are drawn from PMC full text rather than the abstract (notably PMID:25298308) and will therefore fail the --no-full-text check that just validate-disorders and CI run — replace those with abstract-resident quotes or move the claims to notes. Ontology terms need just validate-terms.

Sources

Ontology / database records (retrieved live 2026-08-08) - MONDO:0019262 — OLS4 · MONDO:0008767 — OLS4 · MONDO:0979346 — OLS4 - GeneReviews: Neuronal Ceroid-Lipofuscinoses (NBK1428) - UCL NCL Resource — Mutation and Patient Database - OMIA:000181-9615 — NCL, generic, in dog - GARD: Juvenile neuronal ceroid lipofuscinosis

Primary literature - PMID:21990111 — Kousi, Lehesjoki, Mole. Hum Mutat 2012;33(1):42-63 - PMID:26026925 — Mole & Cotman. Biochim Biophys Acta 2015;1852:2237-41 · PMC4567481 - PMID:22778232 — Williams & Mole. Neurology 2012;79(2):183-91 - PMID:9425237 — Mitchison et al. Hum Mol Genet 1998;7(2):291-7 (juvenile CLN1/GROD) - PMID:23418007 — Sun et al. Hum Mutat 2013;34(5):706-13 (TPP1/SCAR7) - PMID:20157158 — Xin et al. Neurology 2010;74(7):565-71 (CLN5 juvenile) - PMID:34868216 — Front Genet 2021;12:746101 (CLN6 juvenile, no visual loss) · PMC8640139 - PMID:35609511 — Neurodegener Dis 2021;21:126-131 (juvenile-onset Kufs, CLN6) - PMID:19201763 — Kousi et al. Brain 2009;132:810-9 (CLN7/MFSD8) - PMID:25227500 — Roosing et al. Ophthalmology 2015;122(1):170-9 (MFSD8 macular dystrophy) - PMID:10508524 — Ranta et al. Nat Genet 1999;23(2):233-6 (CLN8/EPMR, mnd mouse) - PMID:25298308 — Neurology 2014;83(20):1873-5 (CTSD juvenile ataxia) · PMC4240432 - PMID:16685649 — Steinfeld et al. Am J Hum Genet 2006 (cathepsin D deficiency) - PMID:22388936 — Bras et al. Hum Mol Genet 2012;21(12):2646-50 (ATP13A2/CLN12) - PMID:22608501 — Smith et al. Am J Hum Genet 2012;90(6):1102-7 (GRN dosage) - PMID:31919451 — Jedličková et al. Eur J Hum Genet 2020;28(6):783-9 (DNAJC5, adult NCL gene list) - PMID:15349861 — Schulz et al. 2004 (the "CLN9" variant) - PMID:1535179 — Palmer et al. Am J Med Genet 1992 (SCMAS storage) · PMID:7668326 - PMID:27553520 — Gene 2016;593(2):284-91 (ExAC carrier frequencies) - PMID:23374165 — Orphanet J Rare Dis 2013;8:19 (Italian molecular epidemiology) - PMID:9151309 — Neuropediatrics 1997;28(1):6-8 (Scandinavian epidemiology) - PMID:39281238 — Pak J Med Sci 2024;40(8):1638-43 (pediatric NCL cohort) - PMID:29688815 — Schulz et al. N Engl J Med 2018;378(20):1898-1907 (cerliponase alfa) - PMID:39925015 — Zhang et al. CNS Neurosci Ther 2025;31(2):e70261 - PMID:32300063 — CLN3 Disease Staging System · UBDRS validation, PMC9879304 - Nat Rev Neurol 2025 — NCL mechanisms and therapeutic targets

Trials - NCT03770572 — Gene Therapy for Children With CLN3 Batten Disease · NCT02725580 — CLN6 gene therapy · NCT07582484 — CLN6 scAAV9 · NCT05174039 — Miglustat in CLN3 · NCT03822650 — CLN5 natural history · NCT04644549 — Natural History Study of Batten Disease · NCT03307304 — Investigations of JNCL · CLN7 AAV9 phase 1, PMC12703863

Animal models - Ovine CLN5/CLN6 MRI brain volume, PMC9830986 · Ovine CLN5/CLN6 retinal natural history, PMC8901734 · CLN6 mixed-breed dog, PMC11203140